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ABSTRACT OF DISSERTATION

DEVELOPMENT AND CLINICAL VALIDATION OF KNOWLEDGE-BASED
PLANNING MODELS FOR STEREOTACTIC BODY RADIOTHERAPY OF EARLYSTAGE NON-SMALL-CELL LUNG CANCER PATIENTS
Lung stereotactic body radiotherapy (SBRT) is a viable alternative to surgical
intervention for the treatment of early-stage non-small-cell lung cancer (NSCLC) patients.
This therapy achieves strong local control rates by delivering ultra-high, conformal
radioablative doses in typically one to five fractions. Historically, lung SBRT plans are
manually generated using 3D conformal radiation therapy, dynamic conformal arcs (DCA),
intensity-modulated radiation therapy, and more recently via volumetric modulated arc
therapy (VMAT) on a C-arm linear accelerator (linac). Manually planned VMAT is an
advanced technique to deliver high-quality lung SBRT due to its dosimetric capabilities
and utilization of flattening-filter free beams to improve patient compliance. However,
there are limitations in manual treatment planning as the final plan quality heavily depends
on a planner’s skill and available planning time. This could subject the plan quality to interplanner variability from a single institution with multiple planners. Generally, the standard
lung SBRT patient ‘simulation-to-treatment’ time is 7 working days. This delays clinic
workflow and degrades the quality of treatment by eliminating adaptive re-planning
capabilities. There is an ongoing effort to automate treatment planning by creating a model
library of previously treated, high-quality plans and using it to prospectively generate new
plans termed model-based knowledge-based planning (KBP). KBP aims to mitigate the
previously mentioned limitations of manual planning and improve clinic workflow.
As part of this dissertation, lung SBRT KBP models were created using a
commercially available KBP engine that was trained using non-coplanar VMAT lung
SBRT plans with the final dose reported from an advanced Acuros-based algorithm. The
dissertation begins with the development of a robust and adaptable lung SBRT KBP model
for early-stage, centrally-located NSCLC tumors that is fully compliant with Radiation
Therapy Oncology Group (RTOG)-0813 protocol’s requirements. This new model
provided similar or better plan quality to clinical plans, however it significantly increased
total monitor units and plan complexity. This prompted the development and validation of

an automated KBP routine for SBRT of peripheral lung tumors via DCA-based VMAT per
RTOG-0618 criteria. This planning routine helped incorporate a historical DCA-based
treatment planning approach with a VMAT optimization automated KBP engine that helps
reduce plan complexity. For both central and peripheral lung lesions, the validated models
are able to generate high-quality, standardized plans in under 30 min with minimal planner
effort compared to an estimated 129 ± 34 min of a dedicated SBRT planner’s time. In
practice, planners are expected to meticulously work on multiple plans at once,
significantly increasing manual planning time. Thus, these KBP models will shorten the
‘simulation-to-treatment’ time down to as few as 3 working days, reduce inter-planer
variability and improve patient safety. This will help standardize clinics and enable offline
adaptive re-planning of lung SBRT treatment to account for physiological changes errors
resulting from improper patient set-up.
Lastly, this dissertation sought to further expand these KBP models to support
delivering lung SBRT treatments on a new O-ring linac that was recently introduced to
support underserved areas and fast patient throughput. Despite learning from a C-arm
modality training dataset, these KBP models helped the O-ring linac to become a viable
treatment modality for lung SBRT by providing an excellent plan quality similar to a Carm linac in under 30 min. These KBP models will facilitate the easy transfer of patients
across these diverse modalities and will provide a solution to unintended treatment course
disruption due to lengthy machine downtime. Moreover, they will relieve the burden on a
single machine in a high-volume lung SBRT clinic. Further adaptation and validation of
these KBP models for large lung tumors (> 5 cm) with multi-level dosing scheme and
synchronous multi-lesion lung SBRT is ongoing.
KEYWORDS: Lung SBRT, Knowledge-based Planning, VMAT, Adaptive Re-Planning

Justin David Visak
(Name of Student)
3/19/2021
Date

DEVELOPMENT AND CLINICAL VALIDATION OF KNOWLEDGE-BASED
PLANNING MODELS FOR STEREOTACTIC BODY RADIOTHERAPY OF EARLYSTAGE NON-SMALL-CELL LUNG CANCER PATIENTS
By
Justin David Visak

Damodar Pokhrel, PhD, DABR
Director of Dissertation
Lee Johnson, PhD, DABR
Director of Graduate Studies
3/19/2021
Date

DEDICATION
To Emily, my parents, friends, and family.
.

ACKNOWLEDGMENTS
When I first started as a graduate student at the University of Kentucky in 2017, I
felt the full support of the department in all of my clinical and research endeavors. Whether
specifically named or not, I would like to acknowledge the entire Radiation Medicine
department staff for their support. More specifically, I would like to first acknowledge Dr.
Damodar Pokhrel for advising me and helping to conceptualize this entire dissertation. He
is dedicated to not only supporting me but all students in medical physics. He has played
a large role in the success of this dissertation. With his unmatched guidance, it afforded
me early success and has bolstered my knowledge of medical physics both clinically and
academically.
The next two I would like to thank are Dr. Janelle Molloy and Dr. Marcus Randall.
Dr. Molloy first presented me with this outstanding opportunity and worked closely with
Dr. Randall to help formulate a way to help me complete my PhD. Without their support,
my dissertation and this new program would not have left the ground state. Moreover, I
would like to thank Dr. Ronald McGarry for always making time to discuss topics in his
office with me and offering his unparalleled clinical expertise and support in lung SBRT
throughout this entire PhD dissertation.
To the remaining members of my dissertation committee Dr. Jie Zhang and Dr.
Guoqiang Yu, I would like to thank you for taking the time to support me and for steering
this new PhD program down a successful path. Moreover, I would like to thank Dr. Wayne
Cass for kindly agreeing to sit in on my final thesis defense as an outside examiner. Lastly,
I would like to thank both Dr. Lee Johnson and Dr. Dennis Cheek. Both who have
provided both academic teaching and clinical training throughout my entire time at UK.

iii

TABLE OF CONTENTS

ACKNOWLEDGMENTS ................................................................................................. iii
LIST OF TABLES ............................................................................................................ vii
LIST OF FIGURES ......................................................................................................... viii
CHAPTER 1. INTRODUCTION ...................................................................................... 1
1.1
Management of Lung Cancer.............................................................................. 1
1.1.1 Lung Cancer Prevalence and Current Treatment Options .............................. 1
1.1.2 SBRT Rationale and Development ................................................................. 2
1.2
Overview of Lung SBRT Treatment Planning Techniques ................................ 4
1.2.1 Prescription and Dosing Criteria..................................................................... 4
1.2.2 Forward Planning Lung SBRT ....................................................................... 5
1.2.3 Inverse Planning Lung SBRT ......................................................................... 6
1.3
Knowledge-Based Planning ................................................................................ 8
1.3.1 Advantages of Knowledge-Based Planning.................................................... 8
1.3.2 Dose-Volume Estimation Algorithm ............................................................ 10
1.4
University of Kentucky SBRT Program ........................................................... 13
1.4.1 Lung SBRT Treatments ................................................................................ 13
1.4.2 Expansion of Lung SBRT to Novel O-ring Linac ........................................ 15
1.5
Purpose of Dissertation ..................................................................................... 16
CHAPTER 2. CLINICAL EVALUATION OF PHOTON OPTIMIZER (PO) MLC
ALGORITHM FOR STEREOTACTIC, SINGLE-DOSE OF VMAT LUNG SBRT ..... 18
2.1
Introduction ....................................................................................................... 20
2.2
Methods and Materials...................................................................................... 23
2.2.1 Patient Population and Treatment Planning .................................................. 23
2.2.2 PO-VMAT Plan ............................................................................................ 25
2.2.3 Plan Analysis ................................................................................................ 25
2.3
Results ............................................................................................................... 26
2.4
Discussion ......................................................................................................... 29
2.5
Conclusion ........................................................................................................ 33
CHAPTER 3. DEVELOPMENT AND CLINICAL VALIDATION OF A ROBUST
KNOWLEDGE-BASED PLANNING (KBP) MODEL FOR STEREOTACTIC BODY
RADIOTHERAPY (SBRT) TREATMENT OF CENTRALLY LOCATED LUNG
TUMORS
................................................................................................................... 35
3.1
Introduction ....................................................................................................... 36
3.2
Materials and Methods...................................................................................... 39
3.2.1 Patient Population and Target Definition ..................................................... 39
3.2.2 Clinical n-VMAT Plans ................................................................................ 40
iv

3.2.3 KBP Model Input and Training Datasets ...................................................... 41
3.2.4 Verification of KBP Model ........................................................................... 42
3.2.5 Validation of KBP Model ............................................................................. 44
3.3
Results ............................................................................................................... 46
3.3.1 Dosimetric Criteria........................................................................................ 46
3.3.2 Treatment Planning Time, Delivery Efficiency and Accuracy ..................... 48
3.3.3 Example Validation Case- Left Lower Lobe Tumor .................................... 49
3.3.4 Re-Optimized KBPs with 2.5 mm CGS ....................................................... 51
3.4
Discussion ......................................................................................................... 53
3.5
Conclusion ........................................................................................................ 56
CHAPTER 4. AN AUTOMATED KNOWLEDGE-BASED ROUTINE FOR
STEREOTACTIC BODY RADIOTHERAPY OF PERIPHERAL LUNG TUMORS VIA
DCA-BASED VOLUMETRIC MODULATED ARC THERAPY ................................. 58
4.1
Introduction ....................................................................................................... 59
4.2
Methods............................................................................................................. 62
4.2.1 Patient Population and Clinical Plans ........................................................... 62
4.2.2 Development and Validation of KBP Model ................................................ 62
4.2.3 Dosimetric Comparison Criteria ................................................................... 63
4.2.4 A Novel k-DCA Planning Routine ............................................................... 64
4.2.5 Independent Dose Verification ..................................................................... 65
4.3
Results ............................................................................................................... 65
4.3.1 Clinical Plans vs KBPs ................................................................................. 65
4.3.2 Clinical Plans vs k-DCA Plans ..................................................................... 66
4.3.3 OAR Sparing ................................................................................................. 67
4.3.4 Planning Efficiency and Deliverability ......................................................... 71
4.4
Discussion ......................................................................................................... 72
4.5
Conclusion ........................................................................................................ 75
CHAPTER 5. FAST GENERATION OF LUNG SBRT PLANS WITH A
KNOWLEDGE-BASED PLANNING MODEL ON RING-MOUNTED HALCYON
LINAC
................................................................................................................... 76
5.1
Introduction ....................................................................................................... 77
5.2
Materials and Methods...................................................................................... 81
5.2.1 Patient Selection............................................................................................ 81
5.2.2 Clinical Plans (c-Truebeam) ......................................................................... 82
5.2.3 m-Halcyon Plans ........................................................................................... 83
5.2.4 k-Halcyon Plans ............................................................................................ 84
5.2.5 Plan Dosimetric Evaluation .......................................................................... 84
5.3
Results ............................................................................................................... 85
5.3.1 Target Coverage and Intermediate Dose Fall-Off ........................................ 85
5.3.2 Dose to OAR ................................................................................................. 87
5.3.3 Planning Times and Plan Complexity........................................................... 89
v

5.3.4 Left Upper Lobe Example Case .................................................................... 90
5.4
Discussion ......................................................................................................... 91
5.5
Conclusion ........................................................................................................ 94
CHAPTER 6. INNOVATIONS AND CLINICAL IMPACT.......................................... 96
6.1
Chapter 2: Clinical Evaluation of Photon Optimizer (PO) MLC Algorithm for
Stereotactic, Single-Dose of VMAT Lung SBRT ........................................................ 96
6.2
Chapter 3: Development and Clinical Validation of a Robust KBP Model for
SBRT of Centrally Located Lung Tumors.................................................................... 97
6.3
Chapter 4: An Automated KBP Routine for SBRT of Peripheral Lung Tumors
via DCA-Based VMAT ................................................................................................ 99
6.4
Chapter 5: Fast Generation of Lung SBRT Plans with KBP model on O-ring
Halcyon Linac ............................................................................................................. 101
CHAPTER 7. STUDY LIMITATIONS AND FUTURE RESEARCH DIRECTIONS 104
7.1
7.2

Study Limitations ............................................................................................ 104
Future Research Directions ............................................................................. 106

CHAPTER 8. CLOSING ARGUMENTS ..................................................................... 112
APPENDICES ................................................................................................................ 114
APPENDIX 1. GLOSSARY ....................................................................................... 114
APPENDIX 2. KNOWLEDGE-BASED PLANNING INTERFACE ...................... 116
APPENDIX 3. EXAMPLE PLOTS AND STATISTICS ........................................... 119
APPENDIX 4 EXAMPLE PATIENT WITH DVH AND ESTIMATION ................ 122
REFERENCES ............................................................................................................... 123
VITA ............................................................................................................................... 140

vi

LIST OF TABLES
Table 2.1 Main tumor characteristics of the patients included in this study..................... 24
Table 2.2 Analysis of the target coverage as outlined in RTOG 0915 for all 12 patients
receiving a single dose of VMAT lung SBRT. ................................................................. 26
Table 2.3 Analysis of OAR dosimetric parameters for all 12 lung SBRT patients treated
with a single-dose of 30 Gy VMAT plan.......................................................................... 27
Table 3.1 Selected constraints and their priority for the OAR used to generate the KBP
model. Gen = generated. ................................................................................................... 44
Table 3.2 Patient cohort and tumor characteristics for both training and validation of this
comprehensive and RTOG compliant KBP model. .......................................................... 45
Table 3.3 Evaluation of CI and GI for all plans generated via KBP model for validation.
........................................................................................................................................... 46
Table 3.4 Evaluation of dosimetric lung data for all 20 lung SBRT validation cases. MLD
= mean lung dose. V5, V10, V20 = volume of lung receiving 5 Gy, 10 Gy, 20 Gy or
more. ................................................................................................................................. 47
Table 3.5 Treament delivery efficiency and accuracy of KBP with respect to clinical nVMAT plans. .................................................................................................................... 49
Table 3.6 Average absolute differences of selected target coverage and DVH parameters
for re-optimized KBPs with a 2.5 mm CGS vs original KBPs with 1.25 mm CGS. ........ 52
Table 4.1 Evaluation of plan quality and target indices for all 20 lung SBRT validation
cases generated using KBP or k-DCA routine. ................................................................. 66
Table 4.2 Evaluation of normal lung doses for validation cases generated using KBPs or
k-DCA routine................................................................................................................... 69
Table 4.3 Evaluation of average treatment delivery parameters for validation cases that
were generated using KBP or automated k-DCA routine ................................................. 72
Table 5.1 Validation patient cohort and tumor characteristics. GTV = gross tumor
volume, PTV = planning target volume. ........................................................................... 82
Table 5.2 Evaluation of plan quality and target coverage indicies for all validation cases
including c-Truebeam plans.............................................................................................. 86
Table 5.3 Evaluation of normal lung dosing for lung SBRT validation cases including
original c-Truebeam plans. ............................................................................................... 89
Table 5.4 Evaluation of plan delivery metrics for lung SBRT validation cases including
original c-Truebeam plans. ............................................................................................... 90

vii

LIST OF FIGURES
Figure 2.1 Comparisons of select BEV corresponding MLC control points and isodose
distribution in an axial view between PO and PRO algorithms........................................ 28
Figure 2.2 Comparison of dose volume histograms for target coverage and OARs. ....... 29
Figure 2.3 Ratios of CI, GI, D2cm, GD and select OAR between PO plans vs. clinical
PRO plans. ........................................................................................................................ 31
Figure 2.4 Average MFs and BOTs for PO and PRO MLC Algorithms .......................... 32
Figure 3.1 KBP model training input data selection workflow. ....................................... 42
Figure 3.2 KBP model training workflow. ....................................................................... 43
Figure 3.3 Box plot of maximal pairwise dose differences of KBP compared to n-VMAT
plans. ................................................................................................................................. 48
Figure 3.4 Dose volume histogram comparison for target coverage and OAR dose. ...... 50
Figure 3.5 Comparison of axial and coronal view SBRT isodose distribution for example
patient corresponding to Figure 3.4 .................................................................................. 51
Figure 4.1 Proposed k-DCA treatment planning workflow for peripheral lung SBRT. ... 65
Figure 4.2 Average maximum doses of selected OAR for clinical plans, KBPs and kDCA plans......................................................................................................................... 68
Figure 4.3 Radiosurgical dose colorwash of the clinical plan, KBP and k-DCA plan for a
selected validation case. .................................................................................................... 70
Figure 4.4 Dose volume histogram for the clinical, KBP and k-DCA for corresponding
example case presented in Figure 4.3 ............................................................................... 71
Figure 5.1 Beams-eye-view and description of the new stacked and staggered MLC
design on the Halcyon Linac............................................................................................. 80
Figure 5.2 Average doses to PTV and GTV (Gy) for lung SBRT validation cases
including clinically treated c-Truebeam plans. ................................................................. 87
Figure 5.3 Pairwise dose differences (Gy) of maximal and volumetric dose to OAR for kHalcyon and m-Halcyon plans with respect to c-Truebeam plans. ................................... 88
Figure 5.4 Cumulative dose-volume histogram and corresponding 3-plane view for an
example LUL patient. ....................................................................................................... 91

viii

CHAPTER 1. INTRODUCTION
1.1
1.1.1

Management of Lung Cancer
Lung Cancer Prevalence and Current Treatment Options
Lung cancer is the second most prevalent form of cancer among both men and

women.1 The American Cancer Society estimated in 2020 there were 228,820 new cases
of lung cancer which include approximately 135,720 deaths.1 Of these cases, nearly 84%
are non-small cell lung cancer (NSCLC).1 Early stage (TI-IIN0-M0) NSCLC as defined by
the eight edition TNM stage classification includes tumors ≤ 7 cm, do not have or only
present with regional metastasis in ipsilateral pulmonary/hilar nodes and no distant
metastasis from the primary tumor site.2 To manage these early-stage NSCLC patients,
there are various forms of treatment options available including a combination of surgical
resection, radiation therapy, chemotherapy, targeted agents and immunotherapy.
The most common treatment option for management of early stage I-II NSCLC
without distant node involvement is surgical intervention and has demonstrated a 5-year
survival rate between 56-92% based on metadata analysis.3 The standard of care for
medically inoperable patients, with increasing popularity for operable patients, is lung
stereotactic body radiotherapy (SBRT). Lung SBRT has an established and promising 3year primary tumor control rate of 97% which may provide similar treatment advantages
to surgery for less treatment related toxicity.4 For select patients, cisplatin-based
chemotherapy can be given concomitantly or sequentially with other therapies based on
TNM staging criteria.5 In addition to standard chemotherapy regimens, there is potential

1

for the inclusion of both gene expression targeted agents and immunotherapy check-point
inhibitors as part of patient care.5
1.1.2

SBRT Rationale and Development
While surgical resection offers relatively high 5-year control rates, patients are

often times medically inoperable because they present with an advanced stage tumor,
inaccessible tumor location, or have a comorbidity due to lifestyle or other diseases (i.e.,
chronic obstructive pulmonary disease).6 Surgical intervention may also require a longterm recovery, extended hospital stay, or a potential surgical complication.7,8 For patients
that are operable, they still may deny treatment due to this potential degradation of quality
of life. Therefore, these select early-stage NSCLC patients may receive conventionally
fractioned radiation therapy or lung SBRT; defined as a non-invasive cancer treatment in
which numerous, small, highly-focused and accurate beams deliver a high dose of radiation
(> 6 Gy per fraction), typically in under 5 treatments.4
Prior to the development of lung SBRT treatments, conventional fractionation
radiotherapy delivered 60-70 Gy over 6-7 weeks to the tumor with poor five-year local
control rates of approximately 30 to 50%.9 These unfavorable tumor local control rates led
to the development of a high-dose radiotherapy technique for extracranial malignancies
termed SBRT. At the time of development of the SBRT treatment procedure, Gamma Knife
stereotactic radiosurgery using an external localization device was already widely used in
the management of primary or metastatic intracranial lesions.10 The first major publication
for extracranial SBRT was by Lax et al. where they proposed a method for high-dose
radiotherapy of malignancies in the abdomen.11 By applying pressure on the abdomen, a
stereotactic body frame was described and showed that tumor movement in the liver and
2

lung could be reduced to 5-10 mm 90% of the time.11 Moreover, they proposed an ultrahigh dose can be safely delivered to the tumor using 6-8 non-coplanar beams with rapid
dose fall-off around the target.12 A follow-up study was presented describing 31 patients
treated with 7.7 to 30 Gy per fraction in 1-4 fractions.13 It was concluded that this technique
could offer a convenient SBRT treatment with minimal side-effects for the patients. These
landmark studies served as the foundation for progression into modern SBRT techniques
that will be described in the next section. Many other studies led to the eventual
standardization of lung SBRT.14-18 In the early 2000s, Dr. McGarry and his colleagues
began exploring the potential benefits of lung SBRT for early-stage NSCLC.19 One of the
first studies reported by this Indiana University group was in 2003 that describes a phase I
dose escalation trial starting at 8 Gy per fraction prescribed to the 70-80% isodose line for
3 fractions.14 Patient dose was escalated 2 Gy per fraction every 3-5 patients for a total of
37 patients (maximum up to 24 Gy per fraction for large tumors). It was determined that
patients could tolerate 20 Gy per fraction for a total of 3 fractions (60 Gy total dose). In
2006, the same group launched a phase II trial to confirm the predicted toxicity from the
previous trial along with an attempt to fully evaluate treatment scheme efficacy in a 2
cohort setting where patients received either 60 or 66 Gy in 3 fractions based on staging.18
Another important study, completed by Onishi et al., reported the long term follow data for
87 patients who were medically operable but instead treated with lung SBRT.

16

During

the follow-up interval, median 5-year local control rates were reported between 73-92%
confirming that lung SBRT is potentially comparable to surgery for a non-invasive
treatment with less treatment related side effects.16 Most recently, an ongoing study from
the Veterans Affair’s Office of Research and Development titled Veterans Affairs Lung

3

Cancer Surgery or Stereotactic Radiotherapy (VALOR) aims to determine if surgery or
SBRT is a superior treatment option for stage I NSCLC patients.20
1.2
1.2.1

Overview of Lung SBRT Treatment Planning Techniques
Prescription and Dosing Criteria
In North America, the Radiation Therapy Oncology Group (RTOG) reports

published between 2007-2009 are widely accepted as the modern lung SBRT practicing
guidelines.

21

In general, prescription selection is based on tumor geographical location,

tumor size, staging and surgical candidacy status. These reports detail both tumor
prescription and dosing limits to adjacent organs-at-risk (OAR) for lung SBRT treatments.
For instance, the first report to be described is RTOG-0618 that provided treatment
guidelines for patients with medically operable stage I/II patients with T1-3N0M0 NSCLC
(T3 tumors must have chest wall primary tumors only > 2 cm away from proximal
bronchial tree).21 This protocol originally had a starting fractionation scheme of 60 Gy in
3 fractions, but later it was reduced to 54 Gy in 3 fractions while including tissues
heterogeneity corrections and prescribed dose to the tumor periphery (typically 70-80%
isodose lines).21 Following this report, two reports detailing fractionation schemes specific
to OAR sparing for medically inoperable central and peripheral located tumors were
published.22,23 Centrally located lesions are strictly defined to be tumors within 2 cm or
touching the ‘no-fly-zone’ of the proximal bronchial tree. RTOG-0813 provides
recommendations starting with a fractionation scheme of 50 Gy in 5 fractions for medically
inoperable, centrally located tumors including unique dosing limits to OAR due to toxicity
concern.22 Conversely, RTOG-0915 is a 2-arm study with a dosing protocol consisting of
34 Gy in 1 fraction (Arm 1) or 48 Gy in 4 fractions (Arm 2) for peripherally located NSCLC
4

tumors.23 Moreover, the most recent work of Videtic and colleagues suggests that there is
virtually no differences in tumor local control rates and treatment related toxicity if Arm 1
of the RTOG-0915 protocol is used with a reduced prescription dose of 30 Gy in 1 fraction
rather than 34 Gy. Therefore, for selected patients, in many clinics (including our own)24
around the country this is now the standard prescription for a single treatment of lung
SBRT.25
1.2.2

Forward Planning Lung SBRT
To fully understand the intent of this dissertation, it is important to discuss all

modern lung SBRT treatment planning techniques. 3D-conformal radiation therapy (3DCRT) involves a planner upfront manually choosing treatment parameters for the desired
SBRT plan followed by a dose calculation. This process is known as forward planning and
requires a highly trained and experienced planner to generate a clinically acceptable lung
SBRT plan. Historically, lung SBRT plans were generated using 3D-CRT. Typically, 5-13
static coplanar/non-coplanar beams shaped the targets with 5-10 mm multileaf collimator
(MLC) margins. The planner then proceeds to manually optimize the beam angles,
energies, weighting factors, and MLC apertures based on tumor size, location and
proximity of the OAR. The results of this should generate a high-quality lung SBRT plan
with fast dose fall-off outside the target.26 Additionally, dynamic conformal arcs (DCA)
can be used in lieu of or in combination with static gantry beams for lung SBRT
treatments.27 This benefits the patient as the target remains in the open field throughout the
duration of treatment lessening the chance of interplay between the multi-leaf collimator
position and tumor location while minimizing the concern of small field dosimetry errors.
26,28

However, the major disadvantages of these techniques are there is less dose escalation
5

potential, less normal tissue sparing capabilities, and for static beams may require a
relatively long treatment time that potentially degrades patient comfort.29
1.2.3

Inverse Planning Lung SBRT
Inverse planning of lung SBRT is an advanced treatment planning approach

compared to forward planning and its understanding is vital to this dissertation. In inverse
planning, for a given beam geometry, the planner has the opportunity to input target doses
and normal tissue limits/objectives that define a desired dose distribution upfront. The
planner accomplishes this by inputting a series of target and OAR level dosing optimization
objectives (e.g., maximum dose allowed to OAR, minimum dose coverage to target). To
obtain this desired dose distribution, it requires complex sequencing and movement of the
MLCs, gantry positions or dose rates and is not possible for a human to generate such a
complex treatment plan. Therefore, using an optimization cost function minimization
strategy, a planning software iteratively searches for a fluence map distribution that can
replicate the pre-defined dose distribution when back-projected into the patient anatomy.
There are two clinical techniques that use an inverse planning approach: intensitymodulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT).
IMRT for lung SBRT typically involves delivering treatment using 6-12 beams with a static
gantry position and dose rate with modulating MLCs (i.e., sliding window or step and shoot
methods). The advantage of using IMRT over 3D-CRT is it allows for dose escalation up
to 30% without sacrificing normal tissue sparing.6 However, this significantly increases the
total monitor units and leakage dose. Thus, the complexity of the treatment plan increases
which increases overall treatment time.6

6

Most recently, VMAT paired with a flattening-filter-free (FFF) beam is utilized for
fast delivery of lung SBRT treatments. To treat lung SBRT, 2-4 partial arcs are deployed
with variable MLC openings, dose rate and gantry speed.30 So far, VMAT has shown the
benefits of providing the most conformal treatment with maximized normal tissue sparing
capability. When these treatments are delivered with a FFF beam, the dose rate can be
significantly increased, out-of-field target dose is reduced, and target coverage will be
improved at the lung-tumor interface with respect to the traditional flattened beams.29,31
These benefits may improve patient convenience and ultimately provide a higher-quality
treatment compared to 3D-CRT or IMRT. A few important drawbacks to utilizing a VMAT
technique are it is the most susceptible to the previously described interplay effect and due
to the gantry motion during treatment, it increases treatment delivery difficulty (including
potential risk of patient collisions).8 26
While an inverse planning approach can create a dosimetrically superior lung SBRT
plan compared to traditional 3D-CRT methods, there are practical issues that arise that
should be considered. These limitations are of the upmost importance as they heavily
influence and motivate the purpose of this dissertation. Generating a high quality VMAT
lung SBRT plan typically takes several rounds of iterative optimizations and is much of an
art as it is a science.32 This is primarily due to a patient presenting with difficult planning
geometry, unfavorable tumor location or a large tumor size abutting a dose limiting OAR.
33

Additionally, the final plan quality will depend on a planner’s available treatment

planning time, training and planning experience at their intuition.34 In most radiotherapy
centers, plans are created by a team of dosimetrists (some by well-trained SBRT physicists)
and because the plan quality so heavily depends on an individual planner, an institution is
7

subjected to inconsistent plan quality known as inter-planner variability.35,36 In addition to
variable final plan quality, the standard ‘simulation-to-treatment’ time across many SBRT
clinics around the country is about 7 working days when manually generating a treatment
plan. This long ‘simulation-to-treatment’ time significantly delays clinic workflow, patient
start date, and eliminates a clinic’s ability to perform offline adaptive radiotherapy.37,38
This reduces patient safety, as it is not possible to account for day-to-day physiological
changes or patient setup errors that occur during the course of lung SBRT. These
drawbacks of the inverse planning prompted the development of an automated inverse
planning technique termed knowledge-based planning (KBP) and serves as the
fundamental rationale for this dissertation.
1.3
1.3.1

Knowledge-Based Planning
Advantages of Knowledge-Based Planning
Knowledge-based planning (KBP) is an effort to automate the inverse treatment

planning process, reduce the burden on an individual planner/institution and improve the
treatment plan quality.32 In general, KBP modeling algorithms and software work by using
a model library of previously generated high-quality clinical plans to predict new treatment
parameters for a prospective patient’s plan. This concept was first introduced and
established by research groups from Duke University Medical Center and the Washington
University in St. Louis.39 A study by Chanyavanich et al. was one of the first publications
to introduce this concept in the context of IMRT planning for prostate cancer.40 Here they
developed a knowledge-based approach by using a case similarity algorithm to query
through a model of previously treated prostate IMRT plans and match their 2D beam’s eye
view (BEV) projection image with a new prospective patient’s BEV via mutual
8

information. 40 Once the algorithm matched a prospective plan with a previous reference
plan, the treatment parameters were imported into the new plan and the fluence map was
deformable registered followed by a quick final plan optimization. 40 This study concluded
that their proposed method could generate new plans that were similar or better quality
than previously used clinical plans. Briefly, Moore and colleagues from the University of
Washington in St. Louis developed a model based approach on the degree of overlap of
OAR and the target used to predict mean dose values to those OARs for both head-andneck or rectum treatments.41 These two important studies, among others, effectively
validated that geometric locations of the target and OARs, paired with their respective dose
maps, can generate prospective high-quality treatment plans using mathematical
modeling.42
Knowledge-based planning aims to mitigate some of the unavoidable limitations of
manual inverse planning techniques for lung SBRT treatments and coincides with the
benefits this dissertation proposes. The most important benefit of KBP is that it will remove
inter-planner variability that centers with multiple lung SBRT planners are susceptible
to.43-45 Additionally, KBP aids in creating high-quality and standardized treatment plans
for specified treatment sites.46-48 If implemented effectively, plans will be created in a
clinically relevant shorter planning time and potentially reduce the ‘simulation-totreatment’ time to 3 working days. This will help reduce the planner burden at busy centers
and may aid patients who require an immediate treatment start for aggressive lung tumors.
For those cases, or to account for day-to-day physiological changes and daily patient setup errors, a KBP model could enable a busy clinic to perform offline adaptive
radiotherapy.49 Having an effective KBP model will allow for underlying benefits that
9

include performing quality assurance on previous plans to better assess areas of future
improvement.50,51 These benefits drove the conception and purpose of this dissertation to
be later described.
1.3.2

Dose-Volume Estimation Algorithm
Recently, Varian Medical Systems (Palo Alto, CA) released a knowledge-based

planning dose-volume-histogram algorithm RapidPlanTM that can predict OAR DVHs and
optimization objectives including maximum, mean and a new line dose constraint with
automatically generated priorities. This is achieved by mining specific data from a model
library of previously treated high-quality plans. Our institution recently upgraded our
treatment planning system and acquired a license for RapidPlan DVH estimates that can
be used for lung SBRT planning.
The algorithm has two components, the model configuration and DVH estimate
component.52 In the model configuration part, an appropriate numbers of previously treated
high quality training plans 53 are input into the algorithm to begin data extraction. The exact
number of plans to input is based on the complexity of the tumor site and other factors; too
few plans can result in an undertrained model, conversely, too many plans could result in
overfitting the KBP model. Once the plans are uploaded, the algorithm will parse out each
OAR structure into four voxel regions: in-field, out-of-field, leaf transmission and overlap
reason. For each region a Geometry Expected Dose (GED) histogram, cumulative DVH
and other information will be calculated.52 The GED essentially provides a histogram
relating the fractional volume of the particular OAR to a specified distance away from the
target including dose received by each voxel at that specified distance. Once all relevant
information has been extracted, the training phase of the algorithm begins.
10

For each OAR, a DVH estimation model will be trained that is the sum of four
OAR-region estimation models (i.e., in-field model). There are different ways each regionspecific model is trained depending on desired accuracy of prediction and available training
dataset.36 In general, the in-field region is trained using a principal component analysis
(PCA) regression54 and the remaining regions are trained using a mean and standard
deviation (STD) method. Briefly, for regions using PCA, each DVH and GED histogram
are sampled to represent feature points in a new feature space. The respective principal
components scores (PCS) are found by performing a singular value decomposition (SVD)
on the calculated covariance matrix from the feature space of points.54 The eigenvectors
and eigenvalues are then extracted via the SVD and the algorithm uses these values to
determine the PCSs.

54

The extracted PCSs from the DVH and GED histogram are then

used to find a linear relationship between two selected PCSs for each plan. Once this
relationship is determined, a prospective patient plan’s GED PCSs will be calculated in the
algorithm by multiplying the new GED with the transformation matrix derived from the
learning phase.54 Next, the regression relationship is utilized to obtain the estimated DVH
PCSs. These scores (which represent curves) are added to the average mean DVH of the
database and the final estimated DVH can then be extracted using an inverse
transformation. On a simpler note, the mean and STD DVH for the other regions are used
to predict the new DVH (as specified by the vendor).52 Once the estimates are made, an
upper and lower bound exists and the associated optimization objectives are derived by the
algorithm based on user preference.
Once a model is fully trained, the user must verify and further validate the model
with a separate set of training plans. This typically involves tweaking the model objectives,
11

input mapping of the clinical plans and overall fine adjustments of the model. Meaning,
creating a model is simply not “plug-and-chug.” The goal of verifying a model in essence
is to the check the model’s overall fit and identify both geometric or dosimetric outliers.55
This is accomplished by utilizing the algorithm provided fitting statistics (e.g., R2, modified
Z-score, Cook’s distance), regression or geometric plots, and the cumulative DVH with its
estimated prediction for each training plan (see Appendix). Currently, there is no standard
way to verify the newly generated model and it is incumbent on the user to develop their
own verification procedure (described in a later chapter). A separate set of validation plans
(not used to train the model) should be re-optimized using the DVH estimation algorithm
following further verification. To generate an acceptable KBP model, the vendor
recommends using a minimum of 20 diverse plans 55 (e.g., varied tumor location and size),
but it’s ultimately based on the user’s confidence to verify the model. These validation
KBPs should be carefully examined that the DVH estimates are reasonable and the final
KBP plan is of similar or better quality to the clinical treatment plan. This is a tedious and
time intensive process as one minor tweak to either the training data or user objective will
require all plans are re-validated with the KBP model in its current form. Therefore, it is
mandatory on the user to learn how to determine which model adjustments will fulfill
clinical requirements and further improve the model performance. Upon completion of all
the previously mentioned steps, a KBP model will be ready to be deployed clinically.
In the context of lung SBRT, Chin et al. provided the first KBP RapidPlan model
using 105 plans that included IMRT, VMAT and 3D-CRT treatments.42 As mentioned in
the publication, their model was primarily trained using IMRT plans and concluded KBPs
were of similar or better quality to their respective clinical plans. This study sought to
12

encompass all all tumor geographical locations with a single common RTOG prescription.
As mentioned in later chapters, this is too broad of an approach with KBP modeling and
uses an inferior planning technique; nonetheless this publication served as an important
proof-of-concept for the field going forward. While other sites were preliminarily
investigated,

33,48,56-60

minimal literature exists for lung SBRT KBP models with clinical

application besides the manuscripts generated as part of this dissertation.61-65
1.4

University of Kentucky SBRT Program
The University of Kentucky Medical Center has established constantly growing

stereotactic radiosurgery (SRS) and SBRT programs that includes linac based brain and
spine SRS, prostate, liver and thoracic SBRT treatments. In the context of this dissertation,
the thoracic program herein will be described. For reference, all treatments including lung
SBRT are currently manually optimized by many experienced dosimetrists at our
institution. The results of this dissertation will enable many lung SBRT plans to be created
via recently developed KBP models.
1.4.1

Lung SBRT Treatments
Following diagnosis and selection for lung SBRT treatment, a patient undergoes a

computed tomography (CT) simulation using a respiratory motion management technique
for treatment planning. In our center, patients are immobilized in a Body Pro-LockTM
platform (CIVCO system, Orange City, IA) in the head-first, supine position with arms
above their head including abdominal compression. A free breathing 3D-CT scan is
performed, and images are imported in the Eclipse treatment planning system (TPS). The
region of tissue found to be grossly involved with the lung tumor, gross tumor volume
(GTV), is then delineated by the treating physician.66 To account for tumor motion and
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patient set up errors, a margin of 1.0 cm superior/inferior and 0.5 cm laterally is applied to
the GTV therefore delineating a planning target volume (PTV). If a patient is unable to
undergo abdominal compression, a respiration correlated 4D-CT scan was acquired (along
with the free breathing planning CT scan) and maximum intensity projection (MIP) images
were derived. The free-breathing CT and MIP images were then co-registered, and an
internal target volume (ITV) is created. Meaning, ITV=GTV. Per protocol guidelines, a 0.5
cm uniform margin is applied to the ITV to create the PTV to account for microscopic
disease. All relevant OARs are contoured following target delineation. The University of
Kentucky Medical Center almost exclusively uses a manually generated non-coplanar
VMAT treatment technique for lung SBRT. These patients are primarily treated on a
SBRT-dedicated Varian Truebeam linac (Varian Medical Systems, Palo Alto, CA) with a
nominal 6MV-FFF beam and maximum dose rate setting of 1400 monitor units (MU) per
minute. The major prescriptions utilized for lung SBRT treatments are 50 Gy in 5
treatments or 54 Gy in 3 treatments prescribed to the 60-80% isodose line with no hotspots
allowed outside of the PTV (i.e., hotspots: 120-140%). Recently, for selected lung SBRT
patients, 30 Gy in 1 treatment scheme is also becoming a rising prescription choice at UK.67
Final plan dose is calculated using the advanced Acuros-based dose engine for tissues
heterogeneities corrections. On the day of treatment, a physician is present at the machine
to perform pre-treatment online cone-beam CT (CBCT) imaging for patient alignment and
set up verification. The majority of cases are mostly single lesion; however, the University
of Kentucky Medical Center has treated a growing number of lung SBRT patients who
present with oligometastatic (< 5 lesions) lung tumors.68,69
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1.4.2

Expansion of Lung SBRT to Novel O-ring Linac
Recently, the University of Kentucky Medical Center installed a novel O-ring

Varian Halcyon Linac (V3.0) and aims to expand the busy thoracic and other SBRT
programs to this new platform. This linac was brought to market with the intention of
increasing the speed of patient throughput and advance standard daily fractionated
radiation treatments to the underserved community.70 While not specifically designed for
SBRT, the novel design of the linac with daily kV-CBCT imaging capability allows for
high-quality lung SBRT treatments for selected patients after commissioning for
hypofractioned treatments.71 Historically, the majority of treatments are delivered via a Carm SBRT dedicated linac (Varian Truebeam) which is a vastly different design from the
ring-mounted Halcyon. This linac is equipped with single-energy 6MV-FFF beam, is
jawless and is a coplanar restricted modality. The Halcyon’s 6X-FFF beam is slightly softer
than Truebeam’s with a mean energy and nominal depth of maximum dose of 1.3 MeV at
1.3 cm compared to 1.4 MeV at 1.5 cm, respectively. As of now, Halcyon only allows for
a maximum dose rate setting of 800 MU/min whereas the Truebeam is capable of 1400
MU/min (for 6X-FFF). These mechanical limitations may present difficulty in manually
planning lung SBRT VMAT treatments on Halcyon. A benefit of the new Halcyon design
is the ring-mounted linac is capable of a fourfold increase of rotational gantry speed
compared to Truebeam and is equipped with a new dual-layered stacked and staggered 1
cm wide MLC design.72,73 The new MLC design restricts the field size to 28 × 28 cm2 but
is capable of complete MLC interdigitation whereas the Truebeam allows for a 40 × 40
cm2 maximum field size but does not have full leaf travel. While the larger field size is
useful for many advanced staged disease sites, it does not serve a clinically practical
15

purpose for the relatively small target presentation in lung SBRT treatments. The Halcyon
leaves are less rounded and subsequently have a smaller dosimetric leaf gap (0.1 mm) and
ultra-low leakage and transmission (0.4%) compared to the standard millennium 120 MLC
equipped on Truebeam linac.73,74 Target localization and patient set up verification may be
improved on Halcyon as an advanced iteratively reconstructed on-board CBCT (iCBCT)
scan can be acquired in under 15 seconds. Misalignments can then be corrected with
automatically applied isocenter shifts via a “one-step patient set-up” approach without
manually shifting the patients.75
The Halcyon Linac has demonstrated that it can provide high-quality treatments for
conventionally fractionated cranial, head and neck, prostate and breast treatments.

76-79

Minimal literature exists on Halcyon for stereotactic treatments80-82 and none which
consider the benefits of using a lung SBRT-KBP model to improve treatments and ease the
SBRT planner’s burden to overcome the treatment modality’s limitations.
1.5

Purpose of Dissertation
As previously discussed, manually inverse planning lung SBRT treatments leads

an institution to clinical workflow delays, inconsistent plan quality and restricts offline
adaptive replanning. Additionally, minimal literature exists for lung SBRT planning via
KBP models with either a SBRT-dedicated C-arm or novel ring-mounted linac. There is
no clear guidance or outlined procedure for developing and validating a high-performing,
non-coplanar VMAT lung SBRT KBP model. These planning limitations and lack of
literature provides the foundation for the core objective of this dissertation. Therefore, the
purpose of this dissertation is to develop, validate and explore the clinical benefits of
fully RTOG criteria compliant, non-coplanar VMAT lung SBRT KBP models for
16

medically

inoperable

centrally

located

and

medically

inoperable/operable

peripherally located, early-stage, non-small-cell lung tumors. These fully RTOG
compliant KBP models may be used to treat patients on both a traditional SBRT-dedicated
C-arm linac or transfer patient to a novel O-ring mounted linac. We hypothesized that these
region-specific models would help standardize SBRT plan quality in a busy SBRT clinics
by removing inter-planner variability, improve clinic workflow by significantly shortening
‘simulation-to-treatment’ time to 3 working days, and enabling a clinic to perform offline
adaptive replanning, as needed. Overall, the results of this dissertation will provide a
clearer guidance for future KBP modeling, standardize a clinic’s lung SBRT program in
academic and community centers, and improve patient safety.
Specifically, as part of the first aim of this dissertation, a robust lung SBRT KBP
model for medically inoperable early-stage, centrally-located non-small-cell lung cancer
was developed and validated. Following the first aim, the second aim of this dissertation
developed and validated a robust lung SBRT KBP model for medically inoperable/operable
early-stage, peripherally-located NSCLC patients using a novel DCA-VMAT based
planning technique. Lastly, the third aim of this dissertation adapted and further
generalized the model generated in the first aim to better support lung SBRT treatments on
a novel O-ring linac.

Copyright © Justin David Visak 2021
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CHAPTER 2. CLINICAL EVALUATION OF PHOTON OPTIMIZER (PO) MLC
ALGORITHM FOR STEREOTACTIC, SINGLE-DOSE OF VMAT LUNG SBRT
Prior to generating the lung SBRT RapidPlan KBP models, it was necessary to
dosimetrically characterize and validate the novel Photon Optimizer (PO) MLC positioning
algorithm in the Eclipse TPS against the previously and clinically utilized Progressive
Resolution Optimizer (PRO) algorithm. RapidPlan modeling does not support the PROMLC algorithm. The results of this chapter provided guidance in validating the most
optimal PO-MLC algorithm that is used for generating lung SBRT KBP models. Chapter
2 has been adapted from the recently published manuscript by: Visak J, McGarry RC,
Pokhrel D. Clinical evaluation of photon optimizer (PO) MLC algorithm for stereotactic,
single-dose of VMAT lung SBRT. Med Dosim. 2020; 45(4):321-326
Abstract
Recently implemented Photon Optimizer (PO) MLC optimization algorithm is
mandatory for RapidPlan modeling in Eclipse. This report quantifies and compares the
dosimetry and treatment delivery parameters of PO vs its predecessor Progressive
Resolution Optimizer (PRO) algorithm for a single-dose of volumetric modulated arc
therapy (VMAT) lung stereotactic body radiation therapy (SBRT). Clinical SBRT
treatment plans for 12 early-stage non-small-cell-lung cancer (NSCLC) patients receiving
30 Gy in 1 fraction using PRO-VMAT were re-optimized using the PO-VMAT MLC
algorithm with identical planning parameters and objectives. Average planning target
volume (PTV) derived from the 4D-CT scans was 13.6 ± 12.0 cc (range: 4.3–41.1 cc)
Patients were treated with 6MV flattening filter free (FFF) beam using Acuros-based
calculations and 2.5 mm calculation grid-size (CGS). Both treatment plans were

normalized to receive same target coverage and identical CGS to isolate effects of MLC
positioning optimizers. Original PRO and re-optimized PO plans were compared via
RTOG–0915 protocol compliance criteria for target conformity, gradient indices, dose to
organs at risks (OAR) and delivery efficiency. Additionally, PO-VMAT plans with a 1.25
mm CGS were evaluated. Both plans met RTOG protocol requirements. Conformity
indices showed no statistical difference between PO2.5mm CGS and PRO2.5mm CGS
plans. Gradient index (p = 0.03), maximum dose to 2 cm away from PTV in any direction
(D2cm) (p < 0.05) and gradient distance (p < 0.05) presented statistically significant
differences for both plans with 2.5mm CGS. Some OAR showed statistically significant
differences for both plans calculated with 2.5mm CGS, however no clinically significant
dose differences were observed between the plans. Beam modulation factor was
statistically significant for both PO1.25 mm CGS (p = 0.001) and PO2.5 mm CGS (p <
0.001) compared to clinical PRO2.5mm CGS plans. PO-VMAT plans provided decreased
beam-on time by an average of 0.2 ± 0.1 min (up to 1.0 min) with PO2.5 mm and 1.2 ±
0.39 min (maximum up to 3.22 min) with PO1.25 mm plans compared to PRO2.5 mm
plans. Overall, PO-VMAT single-dose of VMAT lung SBRT plans showed slightly
increased intermediate-dose spillage but boasted overall similar plan quality with less beam
modulation and hence shorter beam-on time. However, PO1.25mm CGS had less
intermediate-dose spillage and analogous plan quality compared to clinical PRO-VMAT
plans with no additional cost of plan optimization. Further investigation into peripheral
targets with PO-MLC algorithm is warranted. This study indicates that PO1.25 mm CGS
plans can be used for RapidPlan modeling for a single-dose of lung SBRT patients. PO-
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MLC 1.25 mm algorithm is recommended for future clinical single dose lung SBRT plan
optimization.
2.1

Introduction
Due to the recent technological advances in radiotherapy, stereotactic body

radiotherapy (SBRT) treatment to solitary primary or metastatic lung lesions for medically
inoperable non-small-cell lung cancer (NSCLC) patients is safe, effective and has a high
cure rate comparable to surgery1-4 including SBRT for elderly patients.5 Moreover, SBRT
is better tolerated by patients with respect to surgery due to its minimal adverse effects. 6
RTOG-0915 protocol (Arm 1) allowed a single-dose of 34 Gy SBRT treatment for earlystage I peripheral NSCLC patients when dosimetric compliance criteria were met. 7 Videtic
et al 8 reported long-term follow up data which revealed no excess late toxicity in either
arm (34 Gy in 1 fraction and 48 Gy in 4 fractions) and demonstrated consistent high rates
of local control. They reported a median overall survival of 4 years for each arm suggesting
similar efficacy. Their study concluded that single-fraction SBRT of 34 Gy remains a
suitable treatment option for patients with early-stage inoperable lung cancer. In another
study, Videtic et al 9 compared 2 single-fraction SBRT dose schemes of 30 Gy and 34 Gy
for 80 medically inoperable early stage-I NSCLC patients. Both treatment schedules
provided equivalent tumor local-control and overall survival rates with minimal toxicity.
Thus, a single-dose of 30 Gy is an equally effective treatment as 34 Gy for the selected
NSCLC patients and is gaining popularity in the clinics.
It has been demonstrated that with respect to traditional SBRT planning methods, 3D
conformal radiation therapy, VMAT provides equal or improved dosimetric delivery.10
Utilizing volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) beams
20

have reduced SBRT treatment time significantly for a single-high dose of radiation and
improved patient compliance.11, 12Removal of the flattening filter from the gantry provides
benefits by reducing head scatter, out-of-field dose, residual electron contamination, and
delivers treatments with higher dose rates up to factors of 2.33 for 6X-FFF and 4 for 10XFFF beams compared to the traditional flattened beams.10,
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Because of the reduced

treatment times, VMAT with FFF beams is particularly appealing for delivering a single
high-dose of SBRT treatment to lung lesions, potentially minimizing intrafraction motion
errors as well.
Recently, Varian Eclipse treatment planning system (TPS, Varian Medical Systems,
Palo Alto CA, Version 13.5) has implemented a new multileaf collimator (MLC)
optimization algorithm called Photon Optimizer (PO).14PO-MLC algorithm was created to
be more efficient for IMRT/VMAT optimization over its predecessor, Progressive
Resolution Optimizer (PRO) algorithm. The main difference between PO and PRO
algorithms is that PO uses a new model for defining structures. For the PO algorithm, the
structures, dose-volume histogram calculations and dose sampling are defined spatially
using a single matrix over the image instead of a point-cloud model defining structures that
was used in the PRO algorithm. In this setting, the PO-MLC algorithm under-samples
voxels at the periphery of the target. However, the PO-MLC setting in Eclipse uses
multiresolution dose calculation approach to increase the dose calculation accuracy. Fixed
voxel resolutions of 1.25 mm, 2.5 mm or 5 mm can be used during multiresolution
optimization.
A few investigators have reported the dosimetric differences of PO-MLC algorithm
for IMRT/VMAT planning in a digital phantom, 15 conventional prostate, head and neck,
21

and brain treatments, 16 knowledge-based planning to rectal cancer patients
fractionated lung SBRT patients and stereotactic brain treatments.
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as well as

For instance, the

advantages and limitations of PO algorithm compared to its predecessor PRO for IMRT
plans were evaluated by Binny et al 16 Eleven plans including prostate, brain, and head and
neck treatments were optimized using both PO and PRO-MLC algorithms in their study.
For similar target coverage and dose to critical structures, they reported that the PO
algorithm gave higher MLC variability and more monitor units. Liu et al 18 compared PO
with PRO algorithms for VMAT planning of fractionated lung SBRT and brain stereotactic
treatments. Their retrospective study included 20 lung SBRT patients (10 received total
dose of 54 Gy in 3 fractions and 10 patients received total dose of 50 Gy in 5 fractions) and
10 brain stereotactic patients received total dose of 25 Gy in 5 fractions. They reported for
identical target coverage, PO algorithm provided comparable plan quality to PRO, with
less MLC complexity, thus improving the treatment delivery efficiency, but contradicting
the results presented by Binny et al.16 Although dosimetric differences with PO algorithm
for lung SBRT plans have been studied previously by Liu et al 18, the dosimetric impact
and treatment delivery complexity of this algorithm with a FFF-beam in the treatment of
single-high dose of 30 Gy in 1 fraction using non-coplanar VMAT lung SBRT planning
with fine resolution dose calculation grid size (CGS) of 1.25 mm has not yet been reported.
Single-fraction lung SBRT (30 Gy in 1 fraction) is an extreme form of
hypofractionation used in our clinic for extracranial lesions where the dose calculation
accuracy could potentially suffer by tumor size, tumor location and the presence of
inhomogeneities in the lung. Moreover, due to under sampling of the voxels at the
periphery of tumor volume by the PO-MLC algorithm, there is a potential for higher
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nontarget normal tissue dose to the organs-at-risk (OAR) adjacent to the tumor periphery.
This consequence will be amplified when delivering a single high-dose of radiation. This
prompted us to quantify the effect of PO-MLC algorithm for our clinical implementation
of a single-high dose of 30 Gy in one fraction protocol using our non-coplanar VMAT lung
SBRT approach. Dose to radiosensitive nontarget OAR is a major worry in VMAT lung
SBRT treatments,
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specifically while delivering a single-large fraction dose as

described here. Therefore, herein, we have retrospectively evaluated 12 consecutive earlystage NSCLC patient’s plans who underwent VMAT-SBRT treatment in our clinic using
the PRO algorithm. For comparison, the clinical PRO-VMAT plans were re-optimized with
the PO algorithm with identical beam geometry and planning objectives. Additionally, POVMAT plans were re-optimized with a fine resolution of 1.25 mm CGS for evaluation. The
original PRO-VMAT and re-optimized PO-VMAT plans were compared by lung SBRT
protocol compliance criteria for the target conformity, gradient indices and dose to OAR
per RTOG requirement. 7

2.2
2.2.1

Methods and Materials
Patient Population and Treatment Planning
After obtaining approval from our institutional review board, this retrospective

study included 12 patients with early stage non-small-cell lung cancer. The patients were
immobilized using Body Pro-LokTM platform (CIVCO system, Orange City, IA) in the
supine position, arms above their head. All planning computed tomography (CT) images
were acquired on a GE Lightspeed 16 slice CT scanner (General Electric Medical Systems,
Waukesha, WI). CT images were acquired with 512 × 512 pixels at 2.5 mm slice thickness.
All patients underwent a free breathing 3D-CT scan followed by a 10-phase 4D-CT scan
23

using Varian’s Real Time Position Management Respiratory Gating System (version 1.7).
Internal target volumes (ITV) were delineated on the 3D CT images with reference to the
MIP images and the planning target volume (PTV) was created by adding a 5 mm uniform
margin around the ITV. Mean PTV derived from 4D-CT scan was 13.6 ± 12.0 cc (range,
4.3-41.1 cc). The critical structures, such as bilateral lungs excluding the ITV (normal
lung), spinal cord, ribs, heart, trachea and bronchus, esophagus, and skin were delineated
on the free-breathing CT images for dose recording. The main tumor characteristics of the
patients included in this retrospective study are shown in Table 2.1.
Table 2.1 Main tumor characteristics of the patients included in this study.
Parameters
Mean ± SD (range or no. of patients)
PTV (cc)
Prescription dose
Normal lung volume (cc)
Laterality (left/right)

13.6 ± 12.0 (4.3 – 41.1)
30 Gy in 1 fraction
4035 ± 1388 (2396 – 6976)
(8/4 patients)

An isocenter was placed at the geometric center of tumor in each patient. Highly
conformal, VMAT treatment plans were generated on the free-breathing 3D-CT images
using 2-6 non-coplanar partial arcs (±5-10o, couch kicks were used) for the Truebeam linear
accelerator (Varian, Palo Alto, CA) with standard millennium MLC and a 6MV-FFF
(1400MU/min) beam. All clinical plans were optimized in Eclipse (version 13.6) with PRO
algorithm using a fixed 2.5 mm voxel resolution. For each arc, collimator angles were
chosen such that the opening of the MLC outside the target was minimized for each patient.
Additionally, the jaw tracking option was chosen during VMAT plan optimization to
further minimize the non-target dose. Advanced Acuros-based dose calculation algorithm
14,21-23

and dose to medium reporting mode was used. A dose of 30 Gy in 1 fraction was

prescribed and at least 95% of the PTV received the prescription dose with the maximum
24

dose to the PTV limited to 130% (hotspots fell within the ITV) of the prescription dose. In
addition to optimization ring structures, the generalized normal tissue objective (NTO)
parameters were used to control the gradients for each target. Planning objectives for the
target coverage and OAR sparing were per RTOG 0915 guidelines. 7
2.2.2

PO-VMAT Plan
The clinical PRO-VMAT treatment plans for all lung SBRT patients were re-

optimized using a recently implemented PO-VMAT MLC algorithm in Eclipse. Identical
beam geometry and planning objectives were used in the PO and PRO plan including the
NTO parameters, ring structures and convergence criteria. The PO plan received the same
target coverage as the clinical PRO. Moreover, PO plans were re-optimized with a fine
resolution of 1.25 mm CGS for further evaluation.
2.2.3

Plan Analysis
The dose volume histograms (DVHs) and isodose curves of clinical PRO and PO

plans were compared. The conformity index (CI) and gradient index (GI) were defined as
the ratios of prescription isodose volume and 50% prescription isodose volume to the PTV
volume, respectively. The gradient distance (GD) was calculated as the average distance
(in any direction) from the PTV margin to the 50% prescription isodose volume whereas
the maximal dose to 2 cm away from the PTV in any direction (D2cm) was calculated per
RTOG 0915 criteria. The dose to the normal lung was evaluated using V5Gy, V10Gy,
V20Gy, mean lung dose (MLD) and maximum dose to 1000 cc of lungs. Furthermore,
dosimetric differences were evaluated for spinal cord, heart, trachea, bronchial tree,
esophagus, ribs and skin following RTOG-0915 requirements. Total number of monitor
units (MU), modulation factor (MF) and beam-on time were compiled. The MF was
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defined as the total number of MU divided by the prescription dose in cGy. Beam-on time
was calculated using total MU divided by the delivered dose rate in minutes. Paired sample
t-test (Microsoft Excel, Microsoft Corp., Redmond, WA) was used to evaluate parameters
for clinical PRO 2.5mm CGS vs PO2.5mm CGS plans using a p-value < 0.05 (two-sided).
Similarly, PRO2.5mm CGS vs PO1.25mm CGS plans were also compared.

2.3

Results
The PO2.5mm CGS plans provided similar plan quality compared to the original

clinical PRO2.5mm CGS optimized plans. As displayed in Table 2.2, PTV parameters per
RTOG 0915 criteria were evaluated. It was confirmed by the study that PO2.5mm CGS
plans were able to reproduce similar conformality for single fraction lung SBRT plans.
However, it is important to note the higher level of intermediate dose spillage with PO
algorithm as shown by the systematically higher values of GI, D2cm and GD (see
statistically significant differences p < 0.05 of these RTOG parameters). This indicates an
increase of intermediate dose-spillage in PO 2.5mm optimized plans.
Table 2.2 Analysis of the target coverage as outlined in RTOG 0915 for all 12
patients receiving a single dose of VMAT lung SBRT.
Parameter
PO2.5 mm CGS
PRO2.5 mm CGS
p-value
CI
1.08 ± 0.073 (0.99 – 1.24)
1.06 ± 0.08 (0.97 – 1.30)
n. s.
GI
5.48 ± 1.09 (3.92 – 7.40)
5.21 ± 0.98 (3.81 – 7.24)
0.03
D2cm (%)
50.08 ± 5.01 (38.520 – 59.50) 47.4 ± 4.64 (37.7 – 55.1)
< 0.05
GD (cm)
1.03 ± 0.177 (0.78 – 1.37)
0.98 ± 0.16 (0.77 – 1.28)
< 0.05
The absolute differences of the averages between the PO2.5mm CGS and
PRO2.5mm CGS for various OAR parameters per RTOG 0915 protocol were analyzed and
displayed in Table 2.3. All values for re-optimized PO2.5mm CGS plans met RTOG 0915
protocol’s requirement with an approximate average absolute difference of less than 1.0
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Gy. There was a statistically significant difference in dose to 1 cc of rib, dose to 10 cc of
skin and the V20Gy in lungs (see, p < 0.05). This reinforces that PO optimized plans exhibit
more intermediate dose-spillage due to the new matrix-based sampling technique. The dose
to 1 cc of rib parameter difference can be explained by the close proximity of PTV volumes
with respect to the ribs in some patients’ plans. It was determined that although there were
a few statistically significant values between the OAR sparing, no clinically significant
differences were discerned due to the small average absolute dose difference between each
OAR.
Table 2.3 Analysis of OAR dosimetric parameters for all 12 lung SBRT patients
treated with a single-dose of 30 Gy VMAT plan.
OAR
DVH Parameter
Absolute Difference (Gy)
p-value
Ribs (Gy)
Maximum
0.88 ± 0.82 (0.16 – 3.02)
n. s.
Dose to 1 cc
0.95 ± 0.86 (0.04 – 3.24)
< 0.05
Cord (Gy)
Maximum
0.23 ± 0.23 (0.0 – 0.72)
n. s.
Dose to 0.35 cc
0.22 ± 0.19 (0.0 – 0.66)
n. s.
Heart (Gy)
Maximum
0.48 ± 0.62 (0.01 – 2.02)
n. s.
Dose to 15 cc
0.30 ± 0.24 (0.04 – 0.70)
n. s.
Esophagus (Gy)
Maximum
0.31 ± 0.21 (0.01 – 0.66)
n. s.
Dose to 3 cc
0.28 ± 0.29 (0.0 – 1.09)
n. s.
Skin (Gy)
Maximum
0.84 ± 0.86 (0.01 – 2.94)
n. s.
Dose to 10 cc
0.16 ± 0.13 (0.02 – 0.50)
< 0.05
Normal lung (%)
V20Gy
0.06 ± 0.04 (0.00 – 0.13)
< 0.05
The beams eye views (BEV) of MLCs (one control point of one arc) and the corresponding
axial views of isodose distributions through the isocenter of a selected patient are shown
for the plans optimized with PO2.5mm CGS and PRO2.5mm CGS in Figure 2.1. The MLC
positions correlate to the same control point for each separately optimized plan. The
PO2.5mm CGS optimized plan shows a larger MLC aperture opening with respect to the
PRO2.5mm CGS optimized plan. It can be observed that even with a significantly different
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MLC aperture, PO-VMAT optimized plans were able to reproduce similar plan quality to
PRO-VMAT plans with less modulation and overall smaller treatment time.

Figure 2.1 Comparisons of select BEV corresponding MLC control points and isodose
distribution in an axial view between PO and PRO algorithms.
Comparisons of the selective BEV corresponding MLC control points (one control point
of arc 1) and isodose distribution in an axial view between the PO (Figure 1C and 1D) and
PRO (Figure 1A and 1B) algorithms for an example patient # 5 (this patient was treated
using 2-partial non-coplanar arcs). PTV size was 41.1 cc at the middle of left upper lobe.
Although both MLC optimizers provided similar target coverage and OAR doses, PO
delivers treatment relatively faster and potentially more accurately due to the decreased
MLC modulation. The PO control points showing larger MLC opening at the PTV margin,
compared to the corresponding PRO control points, was associated with relatively smaller
MU, MF and shorter beam-on time.
An example DVH comparison for the target coverage for the ITV, PTV and a few
OAR are shown for the same example patient #5 in Figure 2.2. This patient’s ITV and
PTV were 10.1 cc and 41.1 cc, respectively and the corresponding PTV diameter of 4.22
cm. For the similar PTV coverage, PO algorithm provided slightly higher dose to the ITV,
while providing similar OAR sparing.
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Figure 2.2 Comparison of dose volume histograms for target coverage and OARs.
Comparison of dose volume histogram for the target coverage and the OAR is shown. The
ITV (red), PTV (orange) and a few OAR such as total normal lung (light blue), ribs (green)
and skin (pink) are shown for the same patient #5. The square symbols representing the
clinical PRO plan, and the triangle symbols representing the PO-MLC plan. Both plans
were normalized to have at least 95% of PTV receiving 100% of the prescribed dose. In
this case, the dosimetrically equivalent plans were generated using PRO vs PO algorithm,
as demonstrated, with similar target coverage and dose to the OAR.
2.4

Discussion
In this report, we investigated the potential improvement of treatment delivery

efficiency while utilizing recently implemented PO-MLC algorithm in the treatment of
single large dose of VMAT lung SBRT patients. For similar target coverage, intermediate
dose spillage and dose to the OAR, our PO VMAT plan provided lower number of MU,
smaller MF and shorter beam-on time compared to PRO plan. Most importantly, the beamon time was improved by 1.0 min, on average (maximum up to 3.12 min) with PO-MLC
algorithm, compared to clinical PRO-MLC algorithm in Eclipse.
While agreeing with those retrospective previous reports, our single-dose of lung
SBRT plans with PO-MLC algorithm exhibited similar target coverage and OAR sparing
compared to clinical PRO plans. Additionally, our PO1.25mm CGS significantly reduced
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beam-on time. Huang et al 24 compared the dosimetric impact of PRO-MLC algorithm and
CGS for lung SBRT patients using 6X-FFF and 10X-FFF beams. AcurosXB and AAA
algorithms were analyzed with 2.5 mm and 1 mm CGS for a total dose of 48 Gy in 4
fractions. They have shown that the dose differences become larger while using higher
energy beam and smaller CGS. However, for the similar target coverage, while reoptimizing PO algorithm with finer resolution of 1.25 mm CGS (smallest resolution
available in Eclipse) we have observed a few clinically interesting results. For instance, in
Figure 2.3 we have shown the ratios of the RTOG target coverage parameters (see left
panel) and a few OAR dose differences (see right panel) between the PO2.5mm CGS and
PO1.25mm CGS as a function of clinical PRO2.5mm CGS plans. It was observed that for
the similar target coverage, there was less intermediate dose spillage (shown by smaller
differences of GI and GD and similar for D2cm) with PO1.25mm CGS (compared to
PO2.5mm CGS). This may indicate PO algorithm with fine resolution will offer similar
dosimetric results with respect to the traditional PRO2.5mm CGS plans. Furthermore, in
some cases the absolute dose differences predicted by PO plans for skin and ribs were
significantly higher up to 2.4 Gy and 3.8 Gy, respectively. Due to these select cases, we
(see Figure 2.3, right panel) suggest the planner to carefully evaluate each plan for dose to
OAR. We believe the large error bars and higher predicted maximum and volumetric dose
in the ribs by the plans optimized with PO1.25mm CGS seen in Figure 2.3 were manifested
by a single lung SBRT plan. In this plan, the target size was relatively small (5.0 cc) directly
abutting the rib cage. As a consequence of this tumor location, a relatively higher density
rib was directly in the beam’s path for the entire duration of the arc rotation, causing
difficulty to accurately predict dose with larger CGS (2.5mm). Therefore, we believe that
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the higher dose predicted in the PO1.25mm CGS was a more accurate representation of the
actual dose to the ribs due to the finer sampling along the periphery of the target. The dose
to 1cc of ribs and 10 cc of skin was evaluated and found to have similar variable dose as
seen by the maximal dose to the ribs (see Figure 2.3). However, 10 cc of skin dose was
similar between the plans. We predict those dosimetric differences (maximal dose to ribs
and skin) and dose to 1 cc of ribs could be clinically significant and need careful assessment
by the planner on the per-patient basis

Figure 2.3 Ratios of CI, GI, D2cm, GD and select OAR between PO plans vs. clinical
PRO plans.
Ratios of CI, GI, D2cm and GD between the PO plans vs clinical PRO plans (left panel)
and the corresponding absolute maximum and volumetric dose differences to skin and ribs
(right panel) for all 12 patients treated with a single high-dose of VMAT lung SBRT. For
similar target coverage, PO algorithm predicted higher maximum doses to the skin and
ribs, including calculating with the fine resolution of 1.25mm CGS.
Comparison of MFs and beam-on times of VMAT lung SBRT plans with
PO1.25mm, PO2.5mm and PRO2.5mm CGSs are shown in Figure 2.4. For the given
complexity of single-large dose of VMAT lung SBRT, it was observed that PO1.25mm
CGS provided the smallest MF and shortest beam-on time among the plans. For a similar
dose distribution, significant reduction of beam delivery complexity was observed with
PO1.25mm CGS (average MF = 2.65 ± 0.51, range: 1.71-3.4) vs. PO2.5mm CGS (average
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MF = 2.73 ± 0.48, range: 2.15-3.53) vs. clinical PRO2.5mm CGS (average MF = 3.19 ±
0.71, range: 2.28-4.8). These plans presented with all p-values < 0.001. The resulting
reduction of average beam on time with PO1.25mm CGS plans compared to PO2.5mm and
PRO2.5mm CGS were 0.2 ± 0.1 min (up to 1.0 min) and 1.2 ± 0.39 min (up to 3.22 min)
respectively. Therefore, by optimizing the VMAT lung SBRT plan with PO1.25mm CGS,
the smaller openings of the MLCs were eliminated that led to less beam modulation and
consequently shorter beam on time, a feature desirable for single dose of lung SBRT. This
suggests more accurate dose delivery due to the reduction in small-field dosimetry
uncertainty.25 Reducing the number of small MLC openings is important for improving
treatment delivery accuracy and reduce small-field dosimetry error in the beam model.

Figure 2.4 Average MFs and BOTs for PO and PRO MLC Algorithms
Left panel: average MFs for PO and PRO-MLC algorithms for 1.25 mm and 2.5 mm CGS
for all 12 patients treated with single-dose of VMAT lung SBRT plan. The corresponding
beam-on time for PO vs PRO algorithms (right panel); significant improvement of the
beam-on time was observed with PO12.5mm CGS with no additional cost of plan
optimization.
Utilizing PO-MLC algorithm with fine resolution of 1.25mm CGS during VMAT
lung SBRT plan optimization potentially reduces MLC complexity and beam-on time
while providing similar target coverage and similar dose to the OAR. However, in some
cases PO-MLC algorithm predicted higher dose to critical structures such as ribs and skin,
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therefore, we suggest carefully evaluating OAR doses on a case-by-case basis. Therefore,
to minimize MLC complexity and consequently beam-on time (based on the presented
results) we strongly recommend utilizing PO-MLC algorithm with fine resolution of
1.25mm CGS (if available) for single-dose of VMAT lung SBRT plan optimization, thus
potentially reducing beam modulation, and transmission and perhaps minimizing unwanted
dose to the patients. This study allows for future work in the development and validation
of a new lung SBRT RapidPlan model using non-coplanar VMAT geometry that supports
advanced Acuros-based dose calculations. It was not previously understood if the PO-MLC
algorithm would be capable of producing high quality non-coplanar VMAT lung SBRT
treatments for a single dose of 30 Gy. Some work has been already done by Snyder et al 26
that successfully generated a RapidPlan model for lung SBRT treatments using
predominately IMRT plans (VMAT and 3DCRT were also included in the model for 3-5
fractions lung SBRT plans) with Varian Anisotropic Analytical Algorithm dose calculation
algorithm. Our new RapidPlan model aims to include these extreme hypofractionated
SBRT plans including other highly conformal non-coplanar VMAT lung SBRT plans with
different fractionation schemes.
2.5

Conclusion
In summary, the potential benefits of utilizing the PO-MLC algorithm on Truebeam

with 6MV-FFF beam for single high-dose of VMAT lung SBRT with curative therapeutic
biological effective dose to lung lesions has been presented. The use of PO-MLC algorithm
for single-dose of VMAT lung SBRT plans optimization showed slightly increased
intermediate-dose spillage but boasted overall similar plan quality with less beam
modulation. Even though PO-MLC algorithm under-sampled voxels at the periphery of the
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target, utilizing fine resolution dose CGS of 1.25 mm overcomes the deficiency of
PO2.5mm CGS and provided lung SBRT plans quality similar to that of clinical
PRO2.5mm CGS plans. Shorter beam-on time can potentially reduce intrafraction motion
errors and improve patient compliance. Smaller beam-modulation and faster treatment
delivery with PO-MLC algorithm suggest that PO1.25mm CGS is suitable for single-dose
of VMAT lung SBRT patients with relatively smaller tumor sizes (< 2cm). This indicates
that RapidPlan modeling can be performed using PO-VMAT plans with fine resolution of
1.25mm CGS for a single-dose of lung SBRT treatments.

Copyright © Justin David Visak 2021
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CHAPTER 3. DEVELOPMENT AND CLINICAL VALIDATION OF A ROBUST
KNOWLEDGE-BASED PLANNING (KBP) MODEL FOR STEREOTACTIC
BODY RADIOTHERAPY (SBRT) TREATMENT OF CENTRALLY LOCATED
LUNG TUMORS
Upon confirmation that the PO-MLC algorithm that was suitable for KBP modeling
of lung SBRT treatments, the first model was developed and validated for centrally located
lung tumors with full RTOG-0813 compliance. Chapter 3 has been adapted from the
recently published manuscript by: Visak J, McGarry RC, Randall ME, Pokhrel D.
Development and clinical validation of a robust knowledge-based planning model for
stereotactic body radiotherapy treatment of centrally located lung tumors. J Appl Clin Med
Phys. 2020; 22(1); 1-10
Abstract
The purpose of this study is to develop a robust and adaptable knowledge-based planning
(KBP) model with commercially available RapidPlanTM for early-stage, centrally-located
non-small-cell lung tumors (NSCLC) treated with stereotactic body radiotherapy (SBRT)
and improve a patient’s ‘simulation to treatment’ time. The KBP model was trained using
86 clinically treated high quality non-coplanar volumetric modulated arc therapy (nVMAT) lung SBRT plans with delivered prescriptions of 50 or 55 Gy in 5 fractions.
Another twenty independent clinical n-VMAT plans were used for validation of the model.
KBP and n-VMAT plans were compared via RTOG–0813 protocol compliance criteria for
conformity (CI), gradient index (GI), maximal dose 2 cm away from the target in any
direction (D2cm), dose to organs-at-risk (OAR), treatment delivery eﬃciency and
accuracy. KBP plans were re-optimized with larger calculation grid size (CGS) of 2.5 mm
to assess feasibility of rapid adaptive re-planning. KBPs were similar or better than n-

VMAT plans based on a range of target coverage and OAR metrics. Planning target volume
(PTV) for validation cases was 30.5 ± 19.1 cc (range 7.0–71.7 cc) KBPs provided an
average CI of 1.04 ± 0.4 (0.97–1.11) versus n-VMAT plan’s average CI of 1.01 ± (0.97–
1.17) (p < 0.05) with slightly improved GI with KBPs (p < 0.05). D2cm was similar
between the KBPs and n-VMAT plans. KBPs provided lower lung V10Gy (p = 0.003),
V20Gy (p = 0.007) and mean lung dose (p < 0.001). KBPs had overall better sparing of
OAR at the minimal increased of average total monitor units and beam-on time by 460 (p
< 0.05) and 19.2 seconds, respectively. Quality assurance phantom measurement showed
similar treatment delivery accuracy. Utilizing 2.5 mm CGS in the final optimization
improved planning time (mean, 5 minutes) with minimal or no cost to the plan quality.
RTOG compliant adaptable RapidPlan model for early-stage SBRT treatment of centrally
located lung tumors was developed. To conclude, all plans met RTOG dosimetric
requirements in less than 30 minutes of planning time, potentially offering shorter
‘simulation to treatment’ times. OAR sparing via KBPs may permit tumoricidal dose
escalation with minimal penalties. Same day adaptive re-planning is plausible with 2.5 mm
CGS optimizer setting.
3.1

Introduction
Stereotactic body radiotherapy (SBRT) for early stage localized non-small cell lung

cancer (NSCLC) has become a significant treatment option to traditional surgical
intervention providing primary tumor local control rates in excess of 97% (median, 3 year).
1,2

Historically, lung SBRT was delivered using 7-13 co/non-coplanar static beams or

dynamic conformal arcs (DCA), followed by intensity modulation radiation therapy
(IMRT) and more recently with volumetric modulated arc therapy (VMAT). 1,3,4 VMAT
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provides more conformal dose-distribution to the target better sparing of organs-at-risk
(OAR) and much faster treatment delivery. The dosimetric advantages of VMAT can be
enhanced using 6MV-flattening filter free (6MV-FFF) beam for lung SBRT because of its
higher dose rates and reduction of out-of-target dose with respect to traditional flattened
beams.5 This provides clinical benefits to the patients as it improves target coverage at the
lung-tumor interface and shorter treatment time; potentially improving patient convenience
and reducing intrafraction motion errors.

6

In North America, the Radiation Therapy

Oncology Group (RTOG) reports provides recommendations to clinicians for SBRT
dosing schemata and contouring guidelines based on operable eligibility and tumor
geographical location. This study concentrates on SBRT for early stage NSCLC patients
with centrally located tumors following RTOG-0813 guidelines.7 In addition to centrally
located lung tumors, our clinic uses this protocol for risk-adapted prescriptions for tumors
located adjacent to critical structures such as the ribs.
Generating an optimal SBRT treatment using a VMAT approach requires multiple
iterations and heavily depends on a planner’s skill. This potentially results in inconsistent
plan quality known as inter-planner variability.8, 9 Automation of inverse planning via
knowledge-based planning (KBP) aims to remove inter-planner variability, improve plan
quality and decrease planning time.10 KBP uses a model library of previously generated
high quality clinical plans to predict new treatment parameters, effectively generating new
plans based on a clinic’s treatment planning history.11 Varian RapidPlan (Varian Medical
Systems, Palo Alto, CA) model is a KBP engine that utilizes a knowledge-based dosevolume histogram (DVH) algorithm to estimate the dose volume histogram (DVH) that
can produce optimization objectives such as maximum, minimum and new line dose
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constraints with associated priority values.12 KBP has demonstrated the ability to create
improved or equivalent plans for prostate, head and neck, spine, breast and thoracic sites.
8,13-18
17

However, there is very limited literature available for lung SBRT treatments,

14, 15,

specifically utilizing highly conformal non-coplanar VMAT (n-VMAT) planning

geometry.
In this report, a RapidPlan model is described to generate adaptable n-VMAT based
KBP treatment plans for early-stage NSCLC patients with medically inoperable centrally
located tumors that follows RTOG-0813 dosing schemata and contouring guidelines. Our
model is exclusively trained with clinically treated high quality n-VMAT lung SBRT plans
using the advanced AcurosXB final dose calculation algorithm. We use the advanced
AcurosXB algorithm for heterogeneity corrections for lung SBRT treatments as it provides
an more accurate dose calculation in heterogeneous patient anatomy by modeling
secondary

build-up

in

tissue/low

density

interfaces

than

traditionally

used

superposition/convolution algorithms.19, 20 The KBP model may permit the improvement
of ‘simulation to treatment’ time from our current average 7 working days to 3 days while
maintaining plan consistency and reducing inter-planner variability. This may enable same
or next day adaptive treatments (if needed) that aim to account for day-to-day changes in
physiological characteristics or setup errors as they occur during a treatment course. A
previous study using a smaller CGS of 1.25 mm vs 2.5 mm in manually optimized VMAT
lung SBRT plans with the Photon Optimizer (PO) algorithm demonstrated minimal
dosimetric differences between the two plans but has not yet been evaluated in a lung SBRT
KBP setting.

21

This led to further evaluation of the concept by generating KBPs with a

CGS of 2.5 mm which drastically decreasing treatment planning time (mean, 5 minutes)
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and observe if they provide similar plan quality to the KBPs plans optimized with a 1.25
mm CGS.
3.2
3.2.1

Materials and Methods
Patient Population and Target Definition
Following approval from our Institutional Review Board (IRB), 106 clinically

treated high quality n-VMAT lung SBRT plans generated for patients with early stage
centrally located tumors as defined by RTOG-0813 were selected for training and
validation. Eighty-six plans were used for training this model and the remaining 20 were
used for validation. Patients received a total of 50 Gy or 55 Gy in 5 fractions. Details of
the patient setup and simulation are published in detail elsewhere.6 Motion control of the
target lesion was accomplished primarily by abdominal compression. If a patient had a
contraindication to abdominal compression e.g., abdominal aortic aneurysm, extensive
abdominal surgery etc., a 4D CT simulation was done to create an internal target volume
(ITV). For patients with abdominal compression, the gross tumor volume (GTV) was
contoured on lung windows and a planning target volume (PTV) was added with margins
of 1.0 cm superior/inferior and 0.5 cm laterally. For patients with 4D CT planning, an ITV
was created from the maximum intensity projections (MIP) on lung windows and a uniform
0.5 cm PTV margin was added uniformly per RTOG 0813 requirements. No clinical target
volume (CTV) was allowed. Organs at risk such as spinal cord, ipsilateral brachial plexus,
skin, esophagus, heart, trachea, total lungs minus PTV, ribs and bronchial tree were
delineated per RTOG-0813 compliance criteria for dose tracking.
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3.2.2

Clinical n-VMAT Plans

For all patients, n-VMAT SBRT plans were generated in the Eclipse treatment planning
system (Varian Medical Systems, Palo Alto CA) using 3–6 (mean, 4) partial non-coplanar
arcs (with ±5-12o couch kicks) on Truebeam Linac (Varian Palo Alto, CA) consisting of
standard millennium 120 MLC and 6MV-FFF (1400MU/min) beam. Jaw tracking option
was enabled for each arc and optimal collimator angles were selected to minimize nontarget dose and enhance plan conformity. Clinical plans were optimized using Photon
Optimizer (v13.6 or v15.6) algorithm with either 1.25 mm or 2.5 mm voxel resolution. The
final dose calculation was performed using advanced AcurosXB algorithm with dose to
medium reporting mode. A dose of 50 Gy or 55 Gy in 5 treatments was prescribed to cover
at least 95% of the PTV receiving 100% of the prescribed dose ensuring that all hotspots
were within the PTV. Before approval, each plan was rigorously evaluated by our treating
physicians via RTOG-0813 compliance criteria and institutional guidelines including dose
to OAR listed below:
•

Conformity index (CI): ratio of 100% isodose line volume to PTV volume, typically
1.0 < CI < 1.2.

•

Gradient index (GI): ratio of 50% isodose line volume to PTV volume, typically
3.0 < GI < 6.0 based on tumor size

•

D2cm (%): maximum dose in any direction 2 cm away from the PTV, typically
50% < D2cm < 70% based on tumor size.

•

Gradient distance (GD): average distance from 100% isodose line to 50% isodose
line, indicator of intermediate dose spillage and sharp fall-off.

•

Total monitor units (MU).
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•

Modulation factor (MF): total number of monitor units divided by the prescription
dose in cGy.

•

Beam-on time (BOT).

•

Dose to OAR: Maximal and volumetric dose to OAR.

3.2.3

KBP Model Input and Training Datasets
An extensive iterative training approach was developed to create this novel and

comprehensive KBP model for SBRT of centrally located lung tumors. Eighty-six nVMAT plans were retrospectively selected and verified to be high quality by evaluating
the numbers of partial arcs and total MU consistency based on historical treatment planning
practice. Original (unaltered) clinical VMAT plans were used for model training. The
primary focus of this plan selection process was examination of RTOG-0813 criteria. Each
plan contour was individually verified to be consistent and correct. A total lung minus
PTV structure was added for each patient’s plan if the structure was not previously created.
Calculation models consisting of dose calculation algorithm, VMAT MLC optimizer and
CGS were verified to be AcurosXB for a 2.5 mm resolution voxel size and photon
optimizer for a 1.25 mm or 2.5 mm voxel size, respectively. Optimal collimator angle and
jaw tracking options were verified prior to input of the training plans. To make the model
fully comprehensive for RTOG compliance, it was necessary to track and select plans of
varying target size and tumor geographical locations (e.g., lower lobe vs upper lobe, right
lung vs left lung) encompassing both lungs (see Table 3.2). Figure 3.1 shows a
summarized workflow of initial plan selection criteria.
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Figure 3.1 KBP model training input data selection workflow.
KBP-model training input data selection workflow for centrally located lung SBRT: A total
of 86 high quality clinical n-VMAT plans were selected to train this model that met RTOG0813 requirements for contouring and OAR dose tolerances while using Acuros-based dose
calculation.
3.2.4

Verification of KBP Model

Verification of a model is a process to evaluate the goodness of fit of the model to ensure
proper generation of each OAR DVH estimate. Model verification was accomplished by
using data provided by the RapidPlan engine to evaluate the R2 fitting values and chisquared values for each DVH estimate provided in the model-training log. If these values
are suboptimal, this is due to the presence of outlier plans in the model. There are two
different types of outliers in the plans: dosimetric and geometric. 14The RapidPlan engine
aids in the removal of outliers; for each OAR it provides in-field DVH plots, geometric
box plots, principal component analysis-regression and residual plots coupled with a
window of different statistics used to gauge a plan’s quality of fit into a model. The
provided regression and residual plots were evaluated for each OAR were used for manual
verification of potential outliers. 22This approach was combined with observing the Cook’s
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distance that indicated influential data points in a regression model and the modified Zscore, which measures the difference of an individual geometric parameter from the median
value in the training set.

25

Once true outliers were identified; the entire plan or specific

outlying structure was removed from the model and all data was re-extracted. A summary
of the KBP model refinement process is shown in Figure 3.2.

Figure 3.2 KBP model training workflow.
KBP-model training workflow: The model was trained by locating and removing the
geometric and dosimetric outliers iteratively.
Constraints were placed on a given OAR following successful verification of the
model to create a fully robust model for centrally located lung tumors and risk adapted
tumor location such as those tumors abutting the rib (see Table 3.1). Theses constraints
were chosen based on RTOG-0813 guidelines and our historical treatment planning
practice.
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Table 3.1 Selected constraints and their priority for the OAR used to generate the
KBP model. Gen = generated.
Structure
Constraint type
Vol [%]
Dose
Priority
Brachial plexus
Upper
5.0
2360 cGy
Gen.
Upper
0
2720 cGy
Gen.
Bronchial Tree
Upper
0.0
105%
Gen.
Line (prefer target)
Gen.
Gen.
Gen.
Spinal cord
Upper
0
2100 cGy
Upper (fixed volume, gen
2.0
Gen.
Gen.
dose)
Line
Gen.
Gen.
Gen.
D2cm
Upper
0.0
50%
110
Line (prefer target)
Gen.
Gen.
Gen.
Esophagus
Upper
0
105%
Gen.
Line (prefer OAR)
Gen.
Gen.
Gen.
Heart
Upper
0.0
105%
Gen.
Line (prefer target)
Gen.
Gen.
Gen.
Ribs
Upper
0
4000 cGy
Gen.
Upper (fixed dose, gen
Gen.
3200 cGy
Gen.
vol.)
Line (prefer target)
Gen.
Gen.
Gen.
Skin
Line (prefer target)
Gen.
Gen.
Gen.
Trachea
Line (prefer target)
Gen.
Gen.
Gen.
3.2.5

Validation of KBP Model
A total of 20 clinical n-VMAT plans that were not used to generate the RapidPlan

model were selected for final verification including recently treated lung SBRT patients
where dedicated manual planning time was recorded (Table 3.2). These plans were
specifically selected to encompass both lungs’ geometry and variable target sizes to fully
test the functionally of our model’s robustness. However, plan quality was not evaluated
prior to selection to ensure the model could produce optimal plans for various case
complexities. The overall validation set included 16 patients who received 50 Gy and 4
patients who received 55 Gy in 5 fractions, respectively. These plans were re-optimized
with the RapidPlan model with identical planning geometry as the clinical n-VMAT plans.
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KBPs were created from a single optimization with no manual intervention. Target dose
coverage for the KBPs was normalized for identical or better target coverage compared to
previously used clinical n-VMAT plans.
To fully assess the performance of this new KBP model, we evaluated the target
conformity, dose-fall off and intermediate dose spillage. Additionally, dose limiting
criteria for organs such as spinal cord, skin, esophagus, trachea, heart, lungs minus PTV,
ribs and bronchial tree were evaluated. Paired student t-test (Microsoft Excel, Microsoft
Corp., Redmond, WA) was used to evaluate KBP vs clinical n-VMAT plans. Plan
complexity was assessed by calculating MF. We also recorded the beam-on time which is
proportional to the changes in MF. Quality assurance phantom measurements of both nVMAT and KBPs were performed using an Octavius detector 1500 and phantom with 7.1
mm center-to-center detector spacing (PTW, Freiburg, Germany) to better assess the
treatment delivery accuracy. KBPs were initially optimized using a 1.25 mm CGS in the
PO MLC algorithm configuration. To assess the feasibility of using this KBP model for
the same day adaptive re-planning, KBPs were re-optimized with a 2.5 mm CGS. Plan
quality and re-optimization time were assessed by comparing to the original KBPs plans.
Table 3.2 Patient cohort and tumor characteristics for both training and validation
of this comprehensive and RTOG compliant KBP model.
Training Set
Validation Set
Tumor location Patients

PTV (cc)

Patients

PTV (cc)

Overall cohort

n = 86

35.7 ± 26.7 (4.4–158.3)

n = 20

30.5 ± 19.1 (7.0–71.7)

Right lower
lobe (RLL)
Right upper
lobe (RUL)

n = 23

42.9 ± 35.2 (10.4–158.3)

n=5

29.4 ± 19.8 (7.5–58.9)

n = 30

29.1 ± 20.1 (4.4–78.7)

n=6

30.3 ± 23.8 (7.0–71.7)
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Table 3.2(continued)
Left lower lobe
(LLL)
Left upper lobe
(LUL)
3.3
3.3.1

n = 16

34.1 ± 27 (9.4–105.3)

n=4

24.1 ± 8.6 (12–33.1)

n = 17

39.1 ± 19.2 (9.0–70.8)

n=5

37.0 ± 16.1 (12.5–51.3)

Results
Dosimetric Criteria
Knowledge based plans were able to provide similar or better target coverage than

clinical n-VMAT plans (Table 3.3). Knowledge based plans had a slightly higher
conformity index of 0.03 (p < 0.05) on average, indicating better overall target coverage
than n-VMAT plans including enhancing minimum dose to GTV. The gradient index was
on average lower by 0.28 for KBP (p < 0.05) suggesting the KBP model was able to provide
a more homogenous dose to the target with sharper and lower intermediate dose spillage.
While a difference in D2cm was not statistically significant, there was a lower difference
in the gradient distance (p < 0.05) suggesting KBPs had a sharper 50% isodose fall off.
Table 3.3 Evaluation of CI and GI for all plans generated via KBP model for
validation.
Target
Parameter
KBP
n-VMAT
p-value
CI
p = 0.002
1.04 ± 0.4 (0.97–1.11)
1.01 ± (0.97–1.17)
GI
4.12 ± 0.9 (3.10–6.53)
4.40 ± 0.7 (3.39–6.01) p = 0.003
HI
1.25 ± 0.05 (1.15–1.35) 1.24 ± 0.06 (1.16–1.39) p = n. s.
D2cm (%)
p = n. s.
51.2 ± 0.4 (0.41–0.57)
50.2 ± 0.4 (44.6–61.6)
PTV
GD (cm)
1.01 ± 0.2 (0.72–1.35)
1.11 ± 0.2 (0.78–1.62) p < 0.001
D99% (Gy)
49.1 ± 2.2 (46.6–54.5)
49.6 ± 2.0 (47.4–53.9) p = 0.004
Mean (Gy)
57.1 ± 2.4 (54.4–62.4)
55.8 ± 2.4 (52.7–61.4) p = 0.003
Max (Gy)
p = n. s.
62.1 ± 3.0 (58.1–69.5)
62.3 ± 2.8 (57.2–67.5)
Min (Gy)
p = 0.05
56.0 ± 3.1 (50.8–62.6)
54.9 ± 3.3 (50.1–61.9)
GTV
Mean (Gy)
p = n. s.
59.6 ± 2.5 (56.2–65.6)
59.1 ± 2.8 (55.4–65.8)
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Dose to normal lung was tracked using mean lung dose, and the volume receiving
5 Gy (V5) 10 Gy (V10) and 20 Gy (V20) or more. These results are shown in Table 3.4.
KBPs had an average lower V5Gy by 0.6%, (p < 0.001), V10Gy by 0.5% (p < 0.001) and
MLD by 0.12 Gy (p < 0.001) suggesting a potentially lower risk of radiation induced
pneumonitis. In addition to normal lung tissue doses, all other OAR compliance criteria
were assessed per RTOG-0813 (Figure 3.3). In many lung SBRT cases, risk-adapted
prescription to targets adjacent to the ribs are used. The greatest sparing achieved in the
KBPs was shown in the ribs (p < 0.001) for an average of 2.62 Gy (maximum up to 9.67
Gy).
Table 3.4 Evaluation of dosimetric lung data for all 20 lung SBRT validation cases.
MLD = mean lung dose. V5, V10, V20 = volume of lung receiving 5 Gy, 10 Gy, 20
Gy or more.
DVH Parameter
KBP
n-VMAT
p-value
V5Gy (%)
p
< 0.001
10.7 ± 5.1 (3.4–19.7)
11.3 ± 5.2 (3.2–21.0)
V10Gy (%)
p < 0.001
6.6 ± 3.8 (2.4–14.1)
7.1 ± 4.1 (2.3–15.4)
V20Gy (%)
p = 0.007
2.7 ± 1.8 (0.7–6.7)
2.8 ± 1.9 (0.8–7.7)
MLD (Gy)
p < 0.001
2.29 ± 1.2 (0.95–4.9)
2.41 ± 1.2 (0.8–5.2)

Our study showed ipsilateral brachial plexus, esophagus, heart, trachea and
bronchial tree received an insignificant average lower dose in KBPs compared to the
clinical n-VMAT plans. Additionally, KBPs on average presented an insignificant but
slightly higher skin dose to spinal cord by 0.46 Gy (p = 0.32).
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Figure 3.3 Box plot of maximal pairwise dose differences of KBP compared to nVMAT plans.
Box plot of maximal pairwise dose differences of KBP compared to n-VMAT plans
displaying median, 10th, 25th, 75th, and 90th percentiles with error bars. Negative values
indicate that KBPs provided less sparing relative to n-VMAT plans. All 20 lung SBRT
cases used for validation were included. Prescription was 50 or 55 Gy in 5 fractions. KBP
model was able to spare maximum rib dose on average by 2.62 Gy (maximum up to 9.67
Gy). Maximum skin dose was on average higher by 0.46 Gy (p = n. s.) but not clinically
significant in KBPs.

3.3.2

Treatment Planning Time, Delivery Efficiency and Accuracy
Knowledge based plans were generated and ready for treatment plan review on

average in under 30 minutes, providing a clinically relevant reduction in treatment planning
time. For an experienced planner with dedicated SBRT planning time, manual plans were
created in 129 ± 34 min, on average (range, 95–183 min). Table 3.5 displays treatment and
delivery efficiency metrics for KBPs and n-VMAT plans. Knowledge based plans on
average only increased total monitor units by 460 (p = 0.008). When considering nominal
maximal dose rates of 6MV-FFF beam (1400MU/min), this results in similar beam on time.
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The minimal values of MF and BOT were increased by 0.46 (p = 0.008), and 19.2 seconds
(p = 0.008), respectively. However, KBPs were still able to provide enhanced GTV dose
and lower dose to OAR.
Table 3.5 Treatment delivery efficiency and accuracy of KBP with respect to clinical
n-VMAT plans.
Treatment delivery
KBP
n-VMAT
p-value
parameter
Total monitor units

3480 ± 531 (2553–4639)

3020 ± 674 (1961–4104)

p = 0.008

Modulation factor

3.48 ± 0.53 (2.53–4.64)

3.02 ± 0.67 (1.92–4.10)

p = 0.008

Beam-on time (min)

2.49 ± 0.34 (1.81–3.31)

2.15 ± 0.48 (1.37–2.93)

p = 0.008

γ-pass rate
[2%/2mm]

94.4 ± 2.7 (90.6–100.0)

95.4 ± 2.3 (90.9–99.4)

p = 0.11

In the patient-specific quality assurance measurements, the gamma analysis of
2%/2 mm criteria was used to assess the plan delivery accuracy differences between KBP
vs clinical n-VMAT plans. KBPs presented with a similar average pass rates of 94.4 ±
2.7% (range, 90.6–100.0%) compared to n-VMAT plans with an average pass rates of 95.4
± 2.3% (range, 90.9–99.4%) (p = 0.11) plans suggesting that comparable treatment delivery
accuracy can be achieved with KBPs.
3.3.3

Example Validation Case- Left Lower Lobe Tumor
Dose volume histograms of both the KBP and n-VMAT plan for a validation case

with a left lower lobe tumor of a lung SBRT patient were generated (Figure 3.4). This
patient was selected as the example case as it best represented the average expectation of
improvement using the KBP model. With better target coverage (minimum dose to GTV
was increased by 2.3 Gy), the KBP model was able to lower volumetric dose to lungs
including MLD, ribs, heart, and bronchial tree. In this case, the maximum rib dose was
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reduced by 4.2 Gy compared to clinical n-VMAT plan. Both plans were normalized so at
least 95% of PTV received 100% of the prescribed dose.

Figure 3.4 Dose volume histogram comparison for target coverage and OAR dose.
Dose volume histogram comparison for the target coverage for the GTV (red) and OAR
such as total normal lung minus PTV (orange), heart (dark blue), ribs (green) and bronchial
tree (dark blue) are shown for an example patient KBP plan (square), and n-VMAT
(triangle). Prescription dose was 50 Gy in 5 fractions. KBP provided superior target
coverage and lower dose to the OAR.

The dosimetrically superior plan was generated using the KBP model, as
demonstrated with slightly better target coverage and volumetrically lower dose to the
OAR including lower maximal dose to rib (Figure 3.5).
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Figure 3.5 Comparison of axial and coronal view SBRT isodose distribution for
example patient corresponding to Figure 3.4
Comparison of KBP vs a clinical n-VMAT plan for the example validation case. The axial
and coronal views of SBRT isodose distributions for the clinical n-VMAT plan (upper
panel) and the corresponding KBP plan (lower panel) are shown. Tumor was located in the
left lower lobe and treated for 50 Gy in 5 fractions. Similar, CI, GI, D2cm, GD and V20Gy
were obtained. A few critical structures shown were ribs, skin, bronchial tree, ipsilateral
normal lung as well as D2cm ring (purple contour). Tighter 50% dose color wash showing
lower rib dose providing slightly better target coverage with KBP plan.
3.3.4

Re-Optimized KBPs with 2.5 mm CGS

The KBP calculation time was dictated by the CGS used in the optimization window. The
original KBPs were calculated with 1.25 mm CGS. However, while using 2.5 mm CGS the
treatment planning time was reduced to approximately 5 minutes. This setting could
support even faster adaptive re-planning in emergent clinical situations. Therefore, KBPs
were re-optimized with a 2.5 mm CGS for plan evaluation. Table 3.6 displays sample
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target coverage and normal tissue sparing dose volume histogram metrics. It was found
that these plans could be created in 5 minutes, on average, with minimal loss of dosimetric
plan quality. Conformity index and gradient index showed no statistical difference between
1.25 mm vs 2.5 mm CGS re-optimized plans. Therefore, KBPs indicate similar conformal
and homogenous target dose coverage with a 2.5 mm CGS. Gradient distance (p = 0.45)
was slightly increased with 2.5 mm CGS configured KBPs signifying an increase in
intermediate dose spillage, however, clinically acceptable and similar V20Gy values were
observed (Table 3.6).
Table 3.6 Average absolute differences of selected target coverage and DVH
parameters for re-optimized KBPs with a 2.5 mm CGS vs original KBPs with 1.25
mm CGS.
Plan metrics
Average difference: 1.25 minus 2.5 mm
p-value
CGS KBPs
Conformity index
0.02 ± 0.02 (0.0–0.06)
p = 0.46
Gradient index

0.32 ± 0.59 (0.0–2.4)

p = 0.93

Gradient distance (cm)

0.03 ± 0.08 (0.0–0.19)

p = 0.04

V20Gy (%)

0.08 ± 0.07 (0.0–0.3)

p = 0.53

Maximum rib dose (Gy)

0.57 ± 0.44 (0.8–1.5)

p < 0.001

Maximum cord dose (Gy)

0.41 ± 0.50 (0.0–2.33)

p = 0.45

DVH Metrics

As shown in Table 3.6, our study found that maximum dose differences for the rib and
spinal cord were not clinically significantly different (similar results were found for other
OAR, not shown here) indicating that 2.5 mm CGS can be used for safe and effective
adaptive re-planning of lung SBRT cases (for selected patients) using this KBP model.
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3.4

Discussion
A fully RTOG-0813 compliant, n-VMAT based KBP model using Varian RapidPlan

was developed and validated for centrally located lung tumors treated with SBRT. This
novel model was fully trained with high quality clinical plans that adhere to contouring,
prescription schemata and dose limits set forth by RTOG-0813 without prior alteration to
input to the model. It is likely that any clinic that complies with RTOG protocol constraints
and are RapidPlan capable can potentially adapt this model to provide high quality nVMAT lung SBRT treatments. To our best knowledge, this novel model is the first
RapidPlan model created exclusively for centrally located tumors using a non-coplanar
VMAT approach with the more accurate Acuros-based dose calculation engine. This
comprehensive KBP model can encompass centrally located lung tumors as well as those
near the ribs.
One of the major benefits of using this RapidPlan model is its possibility of
improving clinic workflow of ‘simulation to treatment’ time from 7 to 3 working days.
While this study recorded an average dedicated planning time of approximately 129
minutes for an experienced planner, in our clinic the majority of our standard 7 working
day ‘simulation to treat time’ comes from planning. We do not have dedicated SBRT
planners and this standard time-slot accounts for not only planner workload but also interplanner variability. Our institution’s planners simultaneously plan multiple treatments per
day and do not have the time to meticulously optimize each lung SBRT plan unlike a
dedicated planner. Additionally, patients who present for re-treatment, have an implanted
pacemaker or any other unique planning difficulty can increase planning time up to a week.
Therefore, the KBP model may allow adaptive re-planning for selected patients with
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incorrect patient set-up on the machine, weight loss or tumor shrinkage that will maintain
high quality SBRT treatment delivery in a timely manner. As expected, for most tumors,
this model can generate a plan of similar or better quality much faster than manual planning
approach, while removing inter-planner variability and standardizing the clinic workflow.
This concept was expanded further by evaluating the effects of the photon optimizer CGS
on a KBP model to evaluate the dosimetric trade-off with decreased treatment planning
time. This appears to be the first study evaluating CGS effects in the context of lung SBRT
KBP planning. It is shown that by utilizing 2.5 mm CGS same day adaptive re-planning is
plausible as planning time was decreased to approximately 5 minutes with minimal
dosimetric impact.
Moreover, the validation cases have shown that slight tumor dose escalation can be
achieved in select lung SBRT cases with similar plan quality to clinical plans and no
penalty to dose limiting organs (DLO). For example, this KBP model can potentially
reduce maximum dose to the rib by 2.62 Gy, on average, while also reducing dose in the
ipsilateral brachial plexus, esophagus, heart, bronchial tree and trachea with no significant
increases to other DLO like spinal cord. Normal lung tissue dosing was also reduced in
KBPs indicated by the reported V5Gy, V10Gy, V20Gy and MLD. Again, these possible
indicators of radiation induced pneumonitis. 23-25This dosimetric OAR sparing and slight
dose escalation of tumor dose was achieved with minimal increase of plan complexity and
overall beam on time. Plan deliverability and small field dosimetry errors were minimal as
seen by similar quality assurance pass rates between the two plans. This indicates that the
optimizer in the KBP model was not significantly modulating the treatment plans more to
achieve better OAR sparing.
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In the past, some investigators have generated KBP models for lung SBRT
treatments. 14,15,17 However, this model is different as it is the first to exclusively consider
centrally located tumors, eliminating varied normal tissue DLO limits due to variable tumor
location and prescriptions as seen in other models. For instance, this work differs from
Chin et al. because they trained their model with a majority of IMRT plans with the less
accurate analytical anisotropic algorithm (AAA) in their training datasets, resulting in
different dosimetric sparing capabilities.14 They reported an average maximum dose
increase to the esophagus of 1.1 Gy in their VMAT validation whereas our KBP model
reduced the maximum esophageal dose by 0.7 Gy, on average. Another study by Delaney,
et al. generated a lung SBRT model for peripheral lesions that considered both a 55 Gy in
5 fractions and 54 Gy in 3 fractions dosing schema.15 Using different prescriptions causes
changes in normal tissue dose limits that can be detrimental to OAR sparing because of
their different biological response to the organs. Our work differs from Delaney et al. as it
fully covers centrally located tumors for a single prescription. The study by Hof, et al.
created a lung VMAT SBRT model to retroactively evaluate patients who developed
greater than grade 3 toxicities in tumors greater than 5 cm in diameter. 17 They used a subset
of their patients (tumors > 5 cm) who did not develop toxicities as a training dataset. Due
to lung toxicity, lung SBRT treatments are typically not done for tumors larger than 5 cm,
so the KBP model described herein was designed for prospective treatment of standard
tumor sizes with centrally located lesions.
A limitation to our work (a common issue in other models) is that some patients’
geometries do not lend themselves to have a treatment ready lung SBRT plan in a single
optimization. This limitation can be broadened to the idea that it is extremely difficult to
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create a KBP model that is fully robust. We found that in atypical cases treatment plans
might need to be manually optimized further following automatic plan generation. While
we feel that using 86 plans for training was sufficient, a few more atypical plans could be
added to the model to better improve robustness of this model. However, there is also a
risk of overfitting the model if too many plans are used for training the model. Future
directions include adding more atypical cases into to further expand this model to tackle
those extremely difficult cases. Our methods described in this work will be expanded next
to generate and further validate a robust lung SBRT RapidPlan model for medically
inoperable/operable early-stage, peripherally located NSCLC patients using a recently
developed dynamic conformal arc-based VMAT planning method that further minimizes
MLC complexity and improves SBRT treatment delivery efficiency and accuracy. 26
3.5

Conclusion
This study created a lung SBRT KBP model via RapidPlan that can quickly generate

a high-quality n-VMAT lung SBRT treatment plan for centrally located lung tumors per
RTOG-0813 protocol. This KBP model is fully comprehensive covering all ranges of
tumor sizes and tumor geographical locations while maintaining adaptability for other
clinics. Using this model, a lung SBRT treatment plan can be generated in less than 30
minutes, on average providing the ability to increase clinic workflow by reducing
‘simulation to treatment’ time down to as few as 3 working days. This activates a clinic’s
ability for online adaptive treatments to selected lung SBRT patients. Treatment planning
time of KBPs was further reduced to 5 minutes while using PO 2.5 mm CGS rather than
1.25 mm in the plan optimization without compromising plan quality. This supports same
or next day adaptive re-planning for selected lung SBRT patients. In addition to improving
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clinical workflow, our model was able to enhance hypoxic tumor core dose while better
sparing critical structures compared to clinical VMAT plans. Moreover, it eliminates interplanner variability, benefiting standardizing lung SBRT treatment planning and improving
patient safety. Clinical implementation of this KBP model will effectively improve overall
clinic workflow and provide high quality, consistent and highly conformal KBP lung SBRT
treatments.

Copyright © Justin David Visak 2021
https://orcid.org/0000-0002-8674-5657
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CHAPTER 4. AN AUTOMATED KNOWLEDGE-BASED ROUTINE FOR
STEREOTACTIC BODY RADIOTHERAPY OF PERIPHERAL LUNG TUMORS
VIA DCA-BASED VOLUMETRIC MODULATED ARC THERAPY
In the previous Chapter 3, a KBP model was developed to aid in the fast treatment
planning of prospective centrally located lung SBRT patients. During the creation of this
model, it was discovered that KBP unintendingly increases total MU and plan complexity.
Therefore, utilizing a traditional DCA-based approach before an automatic VMAT
optimization, a novel routine was developed to design a new KBP model that minimally
impacts current treatment planning workflow and improves the overall plan quality. This
KBP model will significantly reduce the overall plan complexity relative to both manual
and knowledge-based techniques. Herein, Chapter 4 describes this novel routine and has
been adapted from the recently published manuscript by: Visak J, Ge GY, McGarry RC,
Randall M, Pokhrel D. An Automated knowledge-based planning routine for stereotactic
body radiotherapy of peripheral lung tumors via DCA-based volumetric modulated arc
therapy. J Appl Clin Med Phys. 2020; 22(1); 1-10
Abstract
This study aimed to develop a knowledge-based planning (KBP) routine for
stereotactic body radiotherapy (SBRT) of peripherally located early-stage non-small-cell
lung cancer (NSCLC) tumors via dynamic conformal arc (DCA)-based volumetric
modulated arc therapy (VMAT) using the commercially available RapidPlanTM software.
This proposed technique potentially improves plan quality, reduces complexity and
minimizes interplay effect and small field dosimetry errors associated with treatment
delivery. KBP model was developed and validated using 70 clinically treated high quality
non-coplanar VMAT lung SBRT plans for training and 20 independent plans for validation.

All patients were treated with 54 Gy in 3 treatments. Additionally, a novel k-DCA planning
routine was deployed to create plans incorporating historical 3D-conformal SBRT planning
practices via DCA-based approach prior to VMAT optimization in an automated planning
engine. Conventional KBPs and novel k-DCA plans were compared with clinically treated
plans per RTOG-0618 requirements for target conformity, tumor dose heterogeneity,
intermediate dose fall-off and organs-at-risk (OAR) sparing. Treatment planning time,
treatment delivery efficiency and accuracy were recorded. KBPs and k-DCA plans were
similar or better than clinical plans. Average planning target volume for validation was
22.4 ± 14.1 cc (7.1–62.3 cc). KBPs and k-DCA plans provided similar conformity to
clinical plans with average absolute differences of 0.01 and 0.01, respectively. Maximal
doses to OAR were lowered in both KBPs and k-DCA plans. KBPs increased monitor units
(MU) on average 1316 (p < 0.001) while k-DCA reduced total MU on average by 1114 (p
< 0.001). This routine can create k-DCA plan in less than 30 minutes. Independent Monte
Carlo calculation demonstrated that k-DCA plans showed better agreement with planned
dose distribution. In summary, a k-DCA planning routine was developed in concurrence
with a knowledge-based approach for the treatment of peripherally located lung tumors.
This novel method minimizes plan complexity associated with model-based KBP
techniques and improve plan quality and treatment planning efficiency.

4.1

Introduction
Stereotactic body radiation therapy (SBRT) of lung tumors is an alternative treatment

modality to surgery for early stage non-small-cell lung cancer (NSCLC) patients, boasting
local control rates greater than 97% at 3-years. 1-3These outstanding clinical outcomes were
predominantly based on traditional lung SBRT treatments performed with 7 to 13
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coplanar/non-coplanar 3D-conformal static beams or with a few dynamic conformal arcs
(DCA).

4, 5

With modern advances in technology, lung SBRT can be delivered using

intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy
(VMAT). VMAT offers the most conformal dose distribution with higher chances of
sparing organs-at-risk (OAR).6 When coupled with a 6 MV flattening filter free (FFF)
beam, VMAT benefits are enhanced by providing higher dose rates, reduction of out of
field dose and improved coverage at the lung-tumor interface when compared to
traditionally flattened beams. 7, 8
The generation of a high quality VMAT lung SBRT plan can require multiple
iterations of optimization due to difficult patient geometry, tumor size or location. 9 In
general, inverse planning heavily depends on a planner’s experience, treatment planning
time and planner’s skill. Inter-planner variability potentially leads to inconsistent plan
quality and reduced patient safety. 10 Efforts have been made to increase treatment planning
efficiency and plan quality using a form of inverse planning automation known as
knowledge-based planning (KBP). 11 Model-based KBP is a commonly utilized automatic
planning strategy that gathers historical treatment planning data to predict achievable tumor
coverage and OAR doses for a prospective patient.12 This form of KBP has demonstrated
success in creating dosimetrically similar or better plans when compared to manual
planning across many treatment sites with limited but recently increasing literature for lung
SBRT. 12-18
However, a major concern with using KBP for lung SBRT is its tendency to
increase total monitor units (MU) and overall plan complexity

12,18

which can increase

treatment delivery complexity leading to unintended consequences particularly with
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VMAT plans. This includes the interplay effect between MLC motion and the tumor
motion due to breathing cycle.19 VMAT lung SBRT for small tumor sizes (< 3 cm) could
result in small field dosimetry errors.20 These drawbacks are compounded by very high
MLC modulation observed in knowledge-based planning. More traditionally planned 3Dconformal and DCA methods may improve the level of confidence in the treatment. MLC
interplay effect and small field dosimetry errors are reduced improving delivery, efficiency
and accuracy in these plans. 19
Recently, Pokhrel and colleagues have shown that DCA-based VMAT lung SBRT
planning can provide a dosimetrically similar or better plan with reduced complexity when
compared to a standard clinical VMAT lung SBRT plans.

21

Utilizing their approach, in

this study we have developed a novel and automated KBP routine using Varian’s
RapidPlanTM knowledge-based planning engine that couples the benefits of a DCA-based
dose technique with modern knowledge-based VMAT optimization. To deploy this new
and clinically useful technique, it was first necessary to develop and validate a robust noncoplanar VMAT lung SBRT RapidPlan model for medically inoperable/operable earlystage, peripherally located NSCLC patients. This model was created to fully comply with
the RTOG-0618 lung SBRT protocol’s dosing requirements. Its novelty is furthered
because the model uses more accurate advanced Acuros-based dose calculation for
heterogeneity corrections to better predict dose at soft tissue tumor and low-density lung
interfaces. 7, 22, 23
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4.2
4.2.1

Methods
Patient Population and Clinical Plans
Approval from our institutional review board was obtained to utilize 90 clinically

treated patients’ treatment plans for peripherally located early stage, NSCLC tumors that
met the criteria set forth by RTOG-0618. Motion management for these patients was
primarily performed using abdominal compression unless the patient presented with a
comorbidity that did not allow for compression, in these cases a 4D-CT scan was
performed. A gross tumor volume (GTV) was delineated in a lung window and a planning
target volume (PTV) was created with added margins of 1.0 cm superior/inferior and 0.5
cm laterally per protocol guidelines. With the 4D-CT scan, the PTV was generated using a
0.5 cm isotropic margin around the internal target volume (ITV). OARs were contoured
per RTOG-0618 guidelines. Clinical non-coplanar VMAT plans were created in Varian’s
Eclipse treatment planning system (TPS) on a Truebeam Linac (Varian Medical Systems,
Palo Alto, CA). Details of patient set up have previously been published elsewhere. 7 All
patients received a total dose of 54 Gy in 3 fractions prescribed to the 70-80% isodose line.
4.2.2

Development and Validation of KBP Model
The new KBP model was trained and validated using 90 previously treated high

quality non-coplanar VMAT lung SBRT plans. Seventy plans were selected for training
and the remaining 20 plans were used for validation. Prior to input, training and validation
datasets were manually verified to have correct calculation models and grid sizes (e.g., PO
MLC algorithm and Acuros-XB algorithm enabled). Training contours and overall plan
quality were then evaluated for compliance per RTOG-0618 guidelines. Once the KBP
model was verified, normal tissue constraints and dose objectives were iteratively selected.
62

To ensure the KBP model was fully functional and robust, 20 independent patients
were specifically selected to include both lungs’ geometries, differing tumor locations and
variable tumor sizes. This validation dataset included: 6 RUL, 6 LUL, 3 LLL and 5 RLL
patients with an average tumor sizes of 17.0 ± 9.9 cc (7.8–37.5 cc), 19.5 ± 12.1 cc (7.1–
42.9 cc), 38.7 ± 18.2 cc (18.0–62.3 cc), and 22.6 ± 10.2 cc (7.8–37.6 cc) respectively.
Validation plans were re-optimized with the RapidPlan model using identical treatment
geometry as the clinical plans to create the KBP’s. Plans were normalized to have identical
or better target coverage than the original plans.
4.2.3

Dosimetric Comparison Criteria
Re-optimized plans were evaluated for target conformity, dose gradient and

intermediate dose spillage as described by RTOG-0618. Target conformity was assessed
using the conformity index defined as the ratio of the 100% isodose line volume to PTV
volume. Dose gradient was assessed using the RTOG recommended gradient index (GI)
defined the ratio of the 50% isodose line volume to the PTV volume. The maximum dose
2 cm away from the PTV (D2cm) in any direction and the gradient distance (GD), defined
as the average distance between the 100% and 50% isodose lines, were used to quantify
degree of intermediate dose fall-off.
Volumetric and maximum doses to organs at risk outlined by RTOG-0618 were
evaluated. These dose limiting organs (DLO) include the spinal cord, skin, esophagus,
trachea, heart, bronchial tree, ribs and normal lung. The total monitor units divided by
prescription dose in cGy defined as the modulation factor (MF), including beam-on time,
was used to assess plan complexity. An in-house data collection method using the Visual
Eclipse Scripting Application Programming Interface (ESAPI) (Varian Medical Systems,
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Palo Alto, CA), Microsoft Excel (Microsoft corp., Redmond, WA) and MATLAB (Math
Works, Natick, MA) was developed for rapid collection of the aforementioned data. A
paired student t-test was used to assess statistical agreement (p < 0.05 statistically
significant).
4.2.4

A Novel k-DCA Planning Routine
To integrate the benefits of both traditional planning techniques and modern lung

SBRT treatment practices using VMAT optimization, a novel routine was developed to
improve the plan quality and patient safety in prospective treatments. This routine creates
a k-DCA plan using a combination of manual and automated planning approaches with
minimal deviation from traditional planning workflow. To begin, planning geometry is
manually determined by deploying dynamic conformal arcs and collimator angles. An
MLC is then added to each field and is fit with a 2 mm margin around the PTV on each
DCA. Within the PO algorithm (v15.0 or higher) exists the new MLC aperture shaper
controller (ACS). Following creation of planning geometry, the ACS is adjusted from its
default setting of ‘low’ to ‘very high.’ This is modified to aid in the reduction of MLC
modulation in the final plan. Once this aperture setting is applied, a 3D DCA-based dose
is calculated, and field weights are adjusted to give a practical starting point and a base
dose for the future VMAT optimization. Following the DCA-based dose calculation, the
VMAT optimizer is launched and DVH estimates are automatically generated by enabling
the novel KBP model (see section 2B) within the VMAT optimization window. VMAT
optimization is performed using the newly and automatically generated dose optimization
objectives and priorities via the KBP model. Figure 4.1 outlines this process.
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Figure 4.1 Proposed k-DCA treatment planning workflow for peripheral lung
SBRT.
4.2.5

Independent Dose Verification
To verify knowledge-based plans independently, patient-specific quality assurance

was performed using an in-house Monte Carlo (MC) program.24, 25This was performed in
lieu of traditional based quality assurance measurements as recent technological
advancements in online/offline-adaptive re-planning strategies may not allow enough time
to perform a conventional physical measurement. 26 The in-house MC code uses a vendor
provided phase space file to base its functionality off the PENELEOPE MC code.27 Rather
than physical measurement of multi-leaf collimators at the machine, a vendor provided
schematic was used to model in the MC code and independent dose verification. More
details of this algorithm used for this physics second check tool can be found in the cited
literature above.
4.3
4.3.1

Results
Clinical Plans vs KBPs
Knowledge-based plans produced similar or better target coverage than clinical

plans (Table 4.1). Slight dose escalation to the GTV was achieved with KBPs with an
average of 2.2 Gy (p < 0.001). PTV minimum coverage was maintained while slightly
increasing the PTV mean dose (p < 0.001) with no increase in intermediate dose-spillage
with KBPs. This is reflected in both the lower D2cm and the average reduction of 0.1 cm
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in the gradient distance (p < 0.001). For a similar CI, there was significant improvement of
GI with KBPs (p < 0.001) compared to clinical plans indicating less intermediate dose
spillage in normal lung (Table 4.1).
4.3.2

Clinical Plans vs k-DCA Plans
When the proposed automatic planning routine to create a k-DCA plan was

deployed, a higher target dose was achieved at minimal costs to plan quality when
compared to clinical plans. The GTV minimum dose was escalated on average 3.7 Gy in
k-DCA plans. This is due to the increased average MLC aperture size and less MLC
modulation through the target. PTV target metrics showed higher dose with an increase of
mean dose by an average of 2.9 Gy (p < 0.001) with no clinically significant differences in
PTV minimum coverage. Despite the higher delivered GTV dose, the CI differences
between the k-DCA plans and clinical plans were insignificant. As expected, and following
the trend of KBPs, k-DCA plans were more homogenous indicated by the lower GI (p =
0.005) and delivered less intermediate dose spillage reflected in a lower value of GD (p =
0.004). D2cm was slightly increased in k-DCA plans with respect to clinical plans but this
increase was not statistically significant (Table 4.1).
Table 4.1 Evaluation of plan quality and target indices for all 20 lung SBRT
validation cases generated using KBP or k-DCA routine.
Target Parameter Clinical
KBP
k-DCA Clinical Clinical KBP
vs.
vs. kvs. kKBP
DCA
DCA
GTV
Min (Gy)
58.3 ±
60.3 ±
62.0 ±
p=
p<
p=
2.1
2.3
2.1
0.002
0.001
0.002
Mean
62.4 ±
64.6 ±
66.9 ±
p=
p<
p<
(Gy)
1.4
1.9
1.6
0.004
0.001
0.001
Max (Gy)
65.5 ±
67.7 ±
69.3 ±
p=
p<
p<
1.2
1.5
1.6
0.001
0.001
0.001
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Table 4.1 (continued)
PTV

D99%(Gy)
Mean (Gy)
CI
HI
GI
D2cm (%)
GD (cm)

4.3.3

52.3 ±
0.4
59 ±
0.7
1.02 ±
0.03
1.21 ±
0.02
4.56 ±
0.8
49.3 ±
5.6
1.04 ±
0.1

52.5 ±
0.4
61.5 ±
0.8
1.01 ±
0.02
1.27 ±
0.02
3.95 ±
0.5
48.6 ±
4.7
0.94 ±
0.1

52.0 ±
0.6
61.9 ±
0.7
1.03 ±
0.03
1.28 ±
0.02
4.23 ±
0.6
50.6 ±
4.6
0.98 ±
0.1

p = n. s.

p = n. s.

p<
0.001
p = n. s.

p<
0.001
p = n. s.

p<
0.001
p<
0.001
p = n. s.

p<
0.001
p=
0.005
p = n. s.

p<
0.001

p=
0.004

p=
0.002
p=
0.01
p=
0.001
p<
0.001
p<
0.001
p=
0.025
p=
0.05

OAR Sparing
All OAR dosing criteria was assessed per RTOG-0618 protocol’s requirements for

all 20 lung SBRT validation cases. Clinically relevant maximal doses to OAR are shown
in Figure 4.2. Both KBPs and k-DCA plans provided less maximum dose to these select
structures.
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Figure 4.2 Average maximum doses of selected OAR for clinical plans, KBPs and kDCA plans.
Average maximum doses of selected OAR for clinical plans, KBPs and k-DCA plans for
all 20 lung SBRT validation cases. In all cases both KBPs and k-DCA plans were able to
successfully lower the maximum doses delivered to the OAR. KBPs lowered the maximum
rib dose by an average of 1.8 Gy and k-DCA reduced the maximum esophageal dose by
0.9 Gy when compared to clinical plans.
Better OAR sparing can be achieved while still maintaining slight dose escalation
to the tumor using the newly developed KBP model or automated k-DCA routine. The
maximum ipsilateral brachial plexus doses were not clinically significant (not shown).
Volumetric doses were also tracked with notable sparing of 1.0 cc of the ribs in KBPs with
average dose reduction of 0.65 ± 1.28 Gy (0.92–4.0 Gy) and 15 cc of heart in k-DCA plans
with an average dose reduction of 0.97 ± 2.2 Gy (0.2–9.0 Gy) when compared to clinical
plans.
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Table 4.2 Evaluation of normal lung doses for validation cases generated using
KBPs or k-DCA routine.
Target Parameter Clinical
KBP
k-DCA Clinical Clinical KBP vs.
vs. KBP vs. kk-DCA
DCA
LungsV5Gy
12.0 ±
11.0 ±
11.1 ±
p<
p=
p = n. s.
PTV
(%)
4.8
4.4
4.5
0.001
0.006
V10Gy
7.3 ± 3.1
6.7 ±
6.9 ± 3.0
p<
p = n.
p = n. s.
(%)
3.0
0.001
s.
V20Gy
2.8 ± 1.3
2.6 ±
2.5 ± 1.2
p<
p<
p = 0.005
(%)
1.2
0.001
0.001
MLD
2.48 ±
2.25 ±
2.30 ±
p<
p=
p = n. s.
(Gy)
0.9
0.9
0.9
0.001
0.001
Normal lung tissue sparing was tracked for V5Gy, V10Gy and MLD because
literature suggested these better predict radiation-induced pneumonitis than V20Gy

28-30

(Table 4.2). For V5Gy, V10Gy, V20Gy and MLD, KBPs were able to significantly reduce
(all p-values < 0.001) the dose to normal lung when compared to clinical plans. This
suggests that in most cases KBPs show reduced normal lung doses and could potentially
allow for re-treatment in future as needed. Clinical plans delivered higher doses to normal
lung tissue across all metrics when compared to k-DCA plans, however only V5Gy (p =
0.006) and V20Gy (p <0.001) were statistically significant. This could correlate to a
potential lower risk of radiation-induced pneumonitis via k-DCA plans.
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Figure 4.3 Radiosurgical dose color wash of the clinical plan, KBP and k-DCA plan
for a selected validation case.
Radiosurgical dose colorwash of the clinical plan, KBP and k-DCA plan for a selected
validation case. Trachea (light green), esophagus (brown), spinal cord (yellow) and ribs
(dark green) are shown. Clinical plan shows a smaller central hotspot than both KBPs and
k-DCA plan. 50% isodose colorwash was slightly larger in the k-DCA plan but still
clinically acceptable. The largest central hotspot was seen in the k-DCA plan improving
dose to GTV.
A dose color wash distribution with both the axial and coronal views of an example
validation case is shown (Figure 4.3). Corresponding dose-volume histogram is shown in
Figure 4.4. Select OAR are also shown for reference to the tumor location. Highly
conformal radiosurgical dose distribution with a tighter 50% isodose color wash (blue) can
be observed in both clinical and KBPs, however, there was a reduced central hotspot in
both plans when compared to the k-DCA plan. This reflects our findings that k-DCA
routine was able to increase minimum dose to GTV. This larger central hotspot displayed
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in the ¬k-DCA was achieved with minimal to no additional costs in OAR dosing. It is
shown that the 50% isodose color wash was slightly larger in the k-DCA axial slice but
still easily met RTOG-0618 criteria.

Figure 4.4 Dose volume histogram for the clinical, KBP and k-DCA for corresponding
example case presented in Figure 4.3
Dose volume histogram for the clinical plan (squares), KBP (circles) and k-DCA (triangle)
plans corresponding to example case presented in Figure 4.3. PTV (pink), GTV (red), ribs
(green), brachial plexus (orange), trachea (dark green) and lungs-PTV (blue) are presented.
Note for similar OAR sparing, the k-DCA plan significantly increased GTV dose.
4.3.4

Planning Efficiency and Deliverability
The k-DCA plans were generated using plan geometry identical to previously

treated plans in less than 30 minutes. Table 4.3 displays the average values of various
treatment delivery parameters across all 20 lung SBRT validation cases. The most
important result to note here is the significant reduction of total monitor units in the k-DCA
plans due to less MLC modulation through the target. On average, k-DCA plans delivered
1133 and 2460 less MU than clinical plans and KBPs, respectively. This correlates to a
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lower modulation factor, indicating less plan complexity and shorter beam on time. This
validates that k-DCA plans are able to create similar or better-quality plans than manually
generated clinical plans and KBPs with significantly less MLC modulation. Additionally,
the in-house MC second check algorithm reported that the clinical plans (1.8%) and KBPs
(2.4%) on averaged showed less agreement with planned TPS dose with respect to k-DCA
plans (1.0%). This indicates the novel k-DCA planning routine may more accurately
deliver treatment. Additionally, the better MC agreement will provide more confidence in
treatment delivery accuracy for online/offline adaptive lung SBRT.
Table 4.3 Evaluation of average treatment delivery parameters for validation cases
that were generated using KBP or automated k-DCA routine
Treatment
Clinical
KBP
k-DCA
Clinical Clinical KBP
delivery
vs KBP
vs kvs kparameter
DCA
DCA
Total monitor
units (MU)

5488 ±
1018

6804 ±
963

4344 ±
687

p<
0.001

p<
0.001

p<
0.001

Modulation
factor (MF)
Beam-on time
(min)

1.02 ± 0.2

1.26 ± 0.2

0.80 ± 0.1

3.9 ± 0.7

4.9 ± 0.7

3.1 ± 0.5

p<
0.001
p<
0.001

p<
0.001
p<
0.001

p<
0.001
p<
0.001

MC agreement
(%)

±1.76

± 2.40

± 1.03

p = 0.03

p = n. s.

p=
0.002

4.4

Discussion
A novel automatic planning routine was developed to generate a non-coplanar

VMAT lung SBRT k-DCA plans in less than 30 minutes. Both conventional and the kDCA planning routine generates a similar or better-quality plan than manually planning.
This method reduces inter-planner variability and lowers the plan complexity when
compared to original clinical and conventional knowledge-based plans. Better target
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coverage and more DLO sparing was achieved with k-DCA plans because it merges the
benefits of both a historical DCA-based lung SBRT planning approach with a powerful
automatic inverse planning engine. Using the 3D DCA-based dose as a starting point and
optimal machine generated DVH estimates, we have shown that a more accurate lung
SBRT plan can be generated in short period of time compared to typical model-based
knowledge-based planning. Due to less MLC modulation through the target, k-DCA plans
could potentially reduce interplay effect and small-fields dosimetry errors as demonstrated
by better agreement with MC calculation. Nonetheless, it remains incumbent on the
treating physician to review plans in detail to help ensure accuracy and appropriateness of
the objectives of the treatment since there can be intangible goals of the plan that a
computer cannot recognize.
Other investigators have created RapidPlan KBPs for lung SBRT and some
evaluated plan complexity.

12, 16-18

The most recent study by Yu et al. compared clinical

VMAT SBRT plans with both the University of California, San Diego’s publicly shared
RapidPlan VMAT lung SBRT model and robotic CyberKnife plans.

12

They reported on

average an increase of 1025 MU in KBPs when compared to manual clinical plans for a
prescription dose of predominately 50 Gy in 5 fractions. 12 This reflects similar findings in
our study but using our automated k-DCA planning routine we were able significantly
reduce the total MU (see Table 4.3). A study by Delaney et al. produced two RapidPlan
models intended to treat peripheral lung tumors in either 54 Gy in 3 treatments or 55 Gy in
5 fractions.17 For their 55 Gy evaluation patient group, they report average increase of 222
MU for their 5 × 11 Gy model and 188 MU for their combined prescription model
compared to manually generated PO optimized plans.
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17

Additionally, they reported an

increase of monitor units in their 54 Gy evaluation group of 384 MU and 242 MU for their
prescription specific and combined model, respectively. While not as dramatic as the
results shown by Yu et al., 12 there is an apparent increase of MU when using KBPs which
could be accounted for by different choice of planning constraints and model input datasets,
similar to one demonstrated by Kubo et al for conventionally fractionated prostate
radiotherapy. 33With our previous institutional experience, we believe that selecting normal
tissue constraints is a critical process in the creation of a KBP model and it will influence
the performance of the model as much as the initial input dataset selection. Our previous
clinical experience with building a KBP model designed to treat central locations with 50
Gy in 5 fractions scheme also shown increased MU by an average of 261. However, our
automated k-DCA planning routine was able to overcome this issue and maintained
significantly lower total MU and consequently shorter beam-on time. Other KBP models
were generated but did not report total number of MUs.16,18
This automated k-DCA planning routine appears to be the first of its kind and its
novelty is further enhanced when validated independently with MC dose calculations. The
use of the MC code opens the possibility of using this routinely in the clinic for either
online adaptive re-planning or saext day offline adaptive re-planning of lung SBRT
treatment. It has previously been shown that 30 Gy in a single fraction can be delivered to
the lung lesion in a 15-minute time slot. 31 Delivering a single fraction treatment subjects
the plan to delivery potential errors that could greatly enhanced the interplay effect, so our
k-DCA routine could potentially limit this effect by providing less MLC modulation across
the target and improve small-field dosimetry.32 Further validation and clinical
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implementation of this KBP model and automated k-DCA routine for SBRT patient
treatment is underway.
4.5

Conclusion
A novel lung SBRT KBP model for the treatment of peripherally located early-stage

NSCLC tumors as defined by RTOG-0618 was developed and validated. In conjunction
with this model, a first of its kind automated k-DCA planning routine was developed to
generate high-quality lung SBRT plans with less complexity. Utilizing this process, a highquality lung SBRT treatment plan can be generated in as little as 30 minutes with less interplanner variability, allowing for same day or next day adaptive re-planning, if desired. Due
to less MLC modulation through the target and faster treatment delivery, a k-DCA plan
could potentially reduce treatment delivery complexity and intra-fraction motion errors;
improve patient comfort and treatment delivery accuracy.

Copyright © Justin David Visak 2021
https://orcid.org/0000-0002-8674-5657
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CHAPTER 5. FAST GENERATION OF LUNG SBRT PLANS WITH A
KNOWLEDGE-BASED PLANNING MODEL ON RING-MOUNTED HALCYON
LINAC
The previously described KBP models in Chapters 3 and 4 were trained and intended
to treat lung SBRT patients using a non-coplanar VMAT technique with a SBRT-dedicated
C-arm linac. However, with the recently introduced coplanar restricted O-ring Halcyon
linac, it was of great interest to demonstrate whether the previously built KBP model that
was fully trained using highly conformal non-coplanar VMAT plans can be used to develop
an effective KBP model for this novel modality. Therefore, the KBP model from Chapter
3 was adapted to support coplanar treatments geometry with the Halcyon linac. In addition
to reducing ‘simulation-to-treatment’ time, this model intends to reduce the burden on
high-volume lung SBRT clinics and assess the feasibility of quickly transferring patients
between treatment platforms. This provides a solution to unintended longer machine
downtime. Hence, Chapter 5 has been adapted from the recently submitted manuscript by:
Visak J, Webster A, Bernard ME, McGarry RC, Randall M, Pokhrel D. Fast Generation
of Lung SBRT Plans with a Knowledge-based Planning on Ring-Mounted Halcyon Linac.
(Under Review, J Appl Clin Med Phys, submitted on January 10, 2021).
Abstract
This study demonstrates fast treatment planning feasibility of stereotactic body radiation
therapy (SBRT) for centrally located lung tumors on Halcyon Linac via a previously
validated knowledge-based planning (KBP) model to support offline adaptive
radiotherapy. Twenty previously treated non-coplanar volumetric modulated arc therapy
(VMAT) lung SBRT plans (c-Truebeam) on SBRT dedicated C-arm Truebeam Linac were
selected. Patients received 50 Gy in 5 fractions. c-Truebeam plans were re-optimized for

Halcyon manually (m-Halcyon) and with KBP model (k-Halcyon). Both m-Halcyon and kHalcyon plans were normalized for identical or better target coverage than clinical cTruebeam plans and compared for target conformity, dose heterogeneity, dose fall-off, and
dose tolerances to the organs-at-risk (OAR). Treatment delivery parameters and planning
times were evaluated. k-Halcyon plans were dosimetrically similar or better than mHalcyon and c-Truebeam plans. k-Halcyon and m-Halcyon plan comparisons are presented
with respect to c-Truebeam. Differences in conformity index were statistically insignificant
in k-Halcyon and on average 0.02 higher (p=0.04) in m-Halcyon plans. Gradient index was
on average 0.43 (p=0.006) lower and 0.27 (p=0.02) higher for k-Halcyon and m-Halcyon,
respectively. Maximal dose 2cm away in any direction from target was statistically
insignificant. k-Halcyon increased maximal target dose on average by 2.9 Gy (p<0.001).
Mean lung dose was on average reduced by 0.10 Gy (p=0.004) in k-Halcyon and increased
by 0.14 Gy (p<0.001) in m-Halcyon plans. k-Halcyon plans lowered bronchial tree dose on
average by 1.2 Gy. Beam-on-time was increased by 2.85 min and 1.67 min, on average for
k-Halcyon and m-Halcyon. k-Halcyon plans were generated in under 30 minutes compared
to estimated dedicated 180 ± 30 minutes for m-Halcyon or c-Truebeam plans. To
summarize, k-Halcyon plans were generated in under 30 minutes with excellent plan
quality. This adaptable KBP model supports high-volume clinics in the expansion or
transfer of lung SBRT patients to Halcyon.

5.1

Introduction
Surgical resection is an important treatment for early stage non-small-cell lung

cancer (NSCLC) patients. However, many patients are inoperable due to comorbidities,
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refuse surgical resection, or present with a high chance of post-operative morbidity.1, 2 For
these

NSCLC patients, stereotactic body radiation therapy (SBRT) has become an

extremely effective curative treatment modality.2 Compared to poor tumor local-control
rates from conventional lung radiotherapy (60-70% local failure rates), lung SBRT has
provided very high local-control rates up to 97% (median, 3 years actuarial) with less
treatment related toxicity compared to surgery.1-4 To deliver high-quality lung SBRT
treatments, a precise delivered dose must be highly conformal around the tumor with a
steep dose gradient to limit intermediate dose spillage.5 This can be accomplished using
traditional 3D conformal radiation therapy (3D-CRT), intensity-modulated radiation
therapy (IMRT), or more recently via manually generated volumetric modulated arc
therapy (VMAT) plans.6-8 Delivering lung SBRT with VMAT provides enhanced
dosimetric benefits and faster treatments that may aid in patient compliance. 7, 8 Currently,
VMAT lung SBRT treatment is being delivered with flattening filter free (FFF) beams
using a SBRT-dedicated C-arm Linac.2, 9-11FFF beams provide significantly higher dose
rates, less out-of-field scatter dose, less electron contamination and better target coverage
at the tumor-lung interface in comparison to flattened beams.11 These additional benefits
translate to superior treatment in a shorter overall treatment time.

For fast patient throughput and the advancement of standard radiation treatments to
the under-served communities, Varian Medical Systems (Palo Alto, CA) recently
introduced a new jawless, single energy, ring-mounted coplanar restricted Halcyon (V2.0)
medical linear accelerator.12 The Halcyon Linac is equipped with a 6X-FFF beam with a
maximum dose rate setting of up to 800 MU/min, much lower than the 6MV-FFF (up to
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1400 MU/min) beam on a SBRT-dedicated Truebeam Linac. The Halcyon Linac has a
relatively softer beam with a mean energy and nominal maximum depth dose of 1.3 MeV
and at 1.3 cm, compared to the corresponding 6MV-FFF beam on Truebeam of 1.4 MeV
and 1.5 cm. Additionally, Halcyon’s ring-mounted gantry design offers a fourfold increase
in gantry rotation speed when compared to Truebeam and is equipped with a new design
of 1 cm wide dual-layered stacked and staggered MLC (see Figure 5.1).13-14 This design
restricts the field size to 28 × 28 cm2, however, the stacked and staggered MLC design
offers complete leaf interdigitation and allows for MLC travel all the way to 28 cm. With
a less rounded MLC leaf design, the Halcyon boasts a small dosimetric leaf gap of 0.1 mm
and ultra-low leakage and transmission around 0.4%.14,15 This novel MLC design offers
leaf speeds of up to 5.0 cm/s with an effective equivalent 5 mm MLC resolution at the
treatment isocenter. Additionally, target localization is potentially improved with the
Halcyon onboard imager because it has an advanced image reconstruction algorithm that
can iteratively reconstruct a pre-treatment conebeam CT.16 This reconstruction can be
acquired in less than 15 seconds due to the increased gantry speed. Moreover, the new
“one-step patient set up” approach includes automatically applied isocenter shifts that will
significantly reduce patient set up times.

12

One drawback to the Halcyon is that all

treatment plans are restricted to coplanar beam geometry whereas SBRT-dedicated C-arm
linacs allow for larger range of non-coplanarity.
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Figure 5.1 Beams-eye-view and description of the new stacked and staggered MLC
design on the Halcyon Linac
Currently, highly conformal clinical VMAT lung SBRT plans are generated using a
manually optimized inverse planning technique. An issue with manual planning is that the
quality of the final plan depends on individual patient anatomy, planning experience and
available treatment planning time.17,18-24 This potentially leads to inter-planner variability
(i.e., plans with varied dosimetric quality). Knowledge-based planning (KBP) has become
a clinically feasible approach for generating high-quality treatment plans and aims to
mitigate the issues associated with manual planning by standardizing treatment plans and
removing inter-planner variability.18 This is commonly accomplished by using a model
library of previously generated high quality clinical plans to predict new treatment
parameters.19 KBP improves plan quality and drastically reduces treatment planning and
will shorten ‘simulation-to-treatment’ time down to as few as 3 working days. 25 Our center
uses Varian RapidPlan dose-volume histogram estimation algorithm as our KBP engine.
In the past, a few investigators have shown that KBP may help to create dosimetrically
superior or similar lung SBRT plans when compared to manual planning for traditional
SBRT-dedicated C-arm linac treatments.21-25
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Halcyon has been shown to provide fast and effective treatment in the setting of
conventionally fractionated cranial, head and neck, prostate, and breast treatments.

26-28

However, due to the lack of lung SBRT training datasets on Halcyon, there is no literature
that describes training and clinically validating a KBP model for lung SBRT. This
prompted us to evaluate the feasibility of generating lung SBRT plans for centrally located
tumors per RTOG-0813 criteria29 on the Halcyon Linac using a previously validated KBP
model using high-quality non-coplanar Truebeam VMAT plans. It has previously been
demonstrated that lung SBRT using a coplanar geometry produces similar patient outcomes
compared to non-coplanar treatments and that it is feasible to treat lung SBRT on the
Halcyon linac.30,31 The aim of this study was to evaluate the capabilities of KBP modeling
techniques to produce coplanar VMAT plans of similar or better quality on ring-mounted
Halcyon when compared to traditional non-coplanar lung SBRT treatments delivered on a
C-arm Truebeam. We additionally sought to demonstrate whether the Halcyon can
overcome coplanar restrictions with the aid of a previously trained KBP model in the
treatment of centrally located lung tumors using SBRT.
5.2
5.2.1

Materials and Methods
Patient Selection
Institutional review board approval was obtained to conduct this retrospective

study. The previously validated in-house lung SBRT KBP model that was built using
highly-conformal non-coplanar VMAT plans with a patient cohort of 86 patients was
adopted for this study. Details of the model generation have been published.25 Twenty new
patients who were previously treated to 50 Gy in 5 fractions for early-stage I-II NSCLC on

81

SBRT-dedicated Truebeam Linac using non-coplanar VMAT plans were retrospectively
selected to further validate this model on Halcyon Linac.
5.2.2

Clinical Plans (c-Truebeam)
Patients in this cohort were primarily immobilized using the Body Pro-LockTM

system (CIVCO system, Orange City, IA) in the supine position with their arms above the
head and abdominal compression. A free-breathing 3DCT scan was then performed and a
gross target volume (GTV) was delineated followed by a planning target volume (PTV)
with expanded margins of 1.0 cm superior/inferior and 0.5 cm laterally from the GTV. If a
patient was unable to undergo abdominal compression, a respiration-correlated 4DCT scan
using the Varian RPM system (version 1.7) was performed. Maximum intensity projection
(MIP) images were derived from the 4DCT scan, and the images were co-registered to the
free-breathing 3DCT images to delineate an internal target volume (ITV), therefore the
GTV=ITV. The PTV was created by expanding the ITV by 0.5 cm in all directions per
SBRT protocol guidelines. As specified by the RTOG-0813 requirements, all relevant
organs-at-risk (OAR) were contoured (e.g., total lungs, spinal cord, ribs, heart, esophagus
brachial plexus, and skin). For the robust validations of this model, we have included
variable tumor sizes and locations on both lungs’ geometries as shown in Table 5.1.
Table 5.1 Validation patient cohort and tumor characteristics. GTV = gross tumor
volume, PTV = planning target volume.
Tumor location
Overall patient
cohort
Right lower lobe
(RLL)
Right upper lobe
(RUL)

Pop.
n = 20

GTV size (cc)
9.7 ± 13.4 (0.1–61.2)

PTV size (cc)
32.6 ± 25.8 (7.5–114.3)

n=6

13.5 ± 21.7 (0.1–
61.2)
12.8 ± 8.1 (1.6–22.1)

37.0 ± 36.9 (7.5–114.3)

n=5
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43.1 ± 22.1 (11.2–71.7)

Table 5.1 (continued)
Left lower lobe
(LLL)
Left upper lobe
(LUL)

n=4

4.2 ± 1.7 (2.8–7.0)

24.1 ± 8.6 (12–33.1)

n=5

6.6 ± 5.5 (1.0–14.8)

23.7 ± 14.5 (9.7–51.3)

All patients were treated with a highly conformal plan using non-coplanar VMAT
geometry on Truebeam Linac using a 6MV-FFF beam with a maximum dose rate of 1400
MU/min. On average 3-6 non-coplanar partial arcs (±5–12° couch rotations) were utilized
with average arc lengths of approximately 200° and patient-specific collimator angles were
selected to minimize the MLC tongue and groove effect (jaw-tracking enabled). Truebeam
couch and SBRT board were inserted. Isocenter was placed in the center of the PTV and
the dose was prescribed to the 60-80% isodose line and normalized to ensure at least 95%
of the PTV received the full prescription dose of 50 Gy in 5 fractions. All hot-spots
(average: 120-140%) were constrained to be within the GTV. Clinical plans were inversely
optimized using the photon optimizer (PO version 13.0 or 15.0) with final dose calculation
performed using AcurosXB with a 1.25 mm calculation-grid size (CGS) with tissue
heterogeneity corrections.32,33 Dose to medium reporting mode was enabled per our linac
calibration. These patients were treated every other day. On the treatment day, an online
pre-treatment cone-beam CT scan was performed for patient set-up corrections.
5.2.3

m-Halcyon Plans
For comparison, all c-Truebeam lung SBRT plans were manually reoptimized on

Halcyon (m-Halcyon) with identical arc lengths and collimator rotations but using coplanar
geometry. The Truebeam couch was removed and the Halcyon couch and SBRT board
were inserted. As previously described, m-Halcyon plans were reoptimized with the same
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calculation algorithms (with corresponding CGS) and identical planning objectives when
compared to c-Truebeam plans. No jaw tracking option is available on this jawless
Halcyon. The m-Halcyon plans received the same target coverage as the clinical cTruebeam plans.
5.2.4

k-Halcyon Plans
c-Truebeam plans were reoptimized automatically on Halcyon (k-Halcyon) using a

previously validated KBP RapidPlan model. The planning geometry of the k-Halcyon is
identical to m-Halcyon. k-Halcyon plans used the same calculation algorithms and
corresponding CGS but with the automatic planning constraints generated by the
previously validated non-coplanar KBP model. The k-Halcyon plans received the same
target coverage as the clinical m-Halcyon plans.
5.2.5

Plan Dosimetric Evaluation
All plans were dosimetrically evaluated for target conformity, gradient indices and

dose to OAR with RTOG-0813 protocol’s requirements. This included the ratio of
prescription isodose volume to the PTV volume, conformity index (CI), and the ratio of
the 50% isodose volume to the PTV volume known as the gradient index (GI).
Additionally, the maximal dose at 2 cm away from the PTV in any direction (D2cm) was
assessed for intermediate dose fall-off. Supplemental to the RTOG-0813 criteria, our
institution records the gradient distance (GD) defined as the average distance between the
100% and 50% isodose line to further quantify intermediate dose spillage. Moreover, the
heterogeneity index (HI), ratio of PTV maximal dose in cGy and prescription dose were
used to assess hot spots of each plan. In addition to target and plan complexity metrics,
dose to OAR was tracked and documented for maximal and volumetric dosing per RTOG84

0813 criteria. These structures include spinal cord, ipsilateral brachial plexus, skin, total
lung-PTV, esophagus, heart and trachea. Plan complexity was simply assessed by
recording total number of monitor units (MU) and modulation factor (MF). The MF is
defined as the total number of MU divided by the prescription dose in cGy and the
corresponding beam-on time (BOT) was calculated using total MU divided by the
delivered dose rate for each plan. Moreover, overall treatment planning time and results of
independent dose verification via a second physics check Monte Carlo (MC) routine were
recorded.34 To collect and statistically compare these metrics, an in-house data collection
routine was developed using Eclipse Visual Scripting (Varian Medical Systems, Palo Alto)
and MATLAB (Math Works, Natick, MA). Statistical analysis was performed with
Microsoft Excel (Microsoft Corp., Redmond, WA) using a paired student t-test with p <
0.05 signifying statistical significance.
5.3
5.3.1

Results
Target Coverage and Intermediate Dose Fall-Off
Plan quality and target coverage indices are displayed in Table 5.2. All results are

presented for both m-Halcyon and k-Halcyon plans with respect to c-Truebeam plans. Both
m-Halcyon and k-Halcyon produced clinically insignificant differences in conformity
indices indicating similar target coverage. The m-Halcyon plans, on average, produced less
homogenous plans as indicated by the increase of 0.27 in GI (p = 0.02) whereas k-Halcyon
plans provided more homogeneity in target coverage by reducing the GI on average 0.43
(p < 0.005). Across both plans D2cm differences were statically insignificant, however the
GD was much higher in m-Halcyon plans and lower in k-Halcyon plans. This potentially
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indicates less intermediate dose spillage when using knowledge-based planning with
Halcyon Linac.
Table 5.2 Evaluation of plan quality and target coverage indices for all validation
cases including c-Truebeam plans.
Target Para
kmckkm-Halcyon
meter Halcyon Halcyon Truebea Halcyon
Halcyon
vs.cm
vs.mvs.cTruebeam
Halcyon Truebeam
PTV

CI

1.01 ±
0.02

1.03 ±
0.04

1.01 ±
0.04

p = n. s.

p = n. s.

p = 0.04

HI

1.19 ±
0.02
4.22 ±
1.2
50.8 ±
4.9
1.06 ±
0.2

1.16 ±
0.03
4.92 ±
1.3
51.4 ±
5.0
1.17 ±
0.2

1.14 ±
0.04
4.65 ±
1.2
50.5 ±
4.4
1.11 ±
0.2

p < 0.001

p < 0.001

p = n. s.

p < 0.001

p = 0.005

p = 0.02

p = n. s.

p = n. s.

p = n. s.

p < 0.001

p = 0.02

p = 0.002

GI
D2cm
(%)
GD
(cm)

Figure 5.2 displays the average near minimum (D99%) and mean PTV dose
including the average minimum, mean, and maximal doses to GTV for all three plans.
Qualitatively, the near minimum dose to PTV was similar across all three plans (p = n. s.),
however k-Halcyon was able to increase dose across all other metrics indicating slight dose
escalation may be achievable on the Halcyon using KBP model. The PTV mean dose was
55.8 ± 1.61 Gy (53.7–60.6 Gy), 57.8 ± 1.81 Gy (55.7–65.0 Gy) and 55.7 ± 3.0 Gy (53.9–
68.3 Gy) for m-Halcyon, k-Halcyon and c-Truebeam plans, respectively. Additionally, on
average k-Halcyon plans provided higher GTV minimum dose by 1.2 Gy (p = 0.04),
maximum up to 7.6 Gy in some cases.
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Figure 5.2 Average doses to PTV and GTV (Gy) for lung SBRT validation cases
including clinically treated c-Truebeam plans.
Average doses to PTV and GTV (in Gy) for 20 lung SBRT validation cases including
clinically treated c-Truebeam plans. Near minimum PTV (D99%) dose was similar across
c-Truebeam, m-Halcyon and k-Halcyon plans. In general, k-Halcyon provided higher
average dose to PTV and GTV relative to both m-Halcyon and k-Halcyon plans.
5.3.2

Dose to OAR
Maximal and volumetric doses to OAR were recorded per protocol guidelines and

the pairwise differences (in Gy) with respect to clinical c-Truebeam plans are presented in
Figure 5.3. Positive values indicate that both m-Halcyon and k-Halcyon plans provided
higher doses to OAR compared to c-Truebeam plans. In many cases, k-Halcyon plans
helped reduce doses to OAR more than m-Halcyon plans, although these small differences
may not be clinically significant. However, this finding supports the premise that kHalcyon plans on average will be dosimetrically similar or superior to clinical c-Truebeam
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plans and to m-Halcyon. One interesting value to note is that k-Halcyon on average reduced
the maximum rib dose by 1.9 Gy (p = 0.003), maximum up to 6.3 Gy in some cases.

Figure 5.3 Pairwise dose differences (Gy) of maximal and volumetric dose to OAR
for k-Halcyon and m-Halcyon plans with respect to c-Truebeam plans.
Pairwise dose differences (in Gy) of maximal and volumetric dose to OAR for k-Halcyon
and m-Halcyon plans with respect to c-Truebeam plans. Positive values indicate respective
plans on average provided a higher dose to OAR compared to c-Truebeam plans. kHalcyon plans across many dosing metrics delivered lower OAR doses than m-Halcyon
including an average 0.74 Gy reduction in maximal dose to heart.

Dose to normal lung was evaluated using V5Gy, V10Gy, V20Gy and mean lung dose (Gy)
as all of these metrics have been correlated to radiation-induced pneumonitis and recently,
may correlate with overall survival in stage I lung cancer.35-37 These results are shown in
Table 5.3. k-Halcyon plans on average reduced all normal lung dosing metrics whereas mHalcyon increased values when compared to c-Truebeam plans. The largest differences in
dose to normal lung were recorded for V5Gy. There was a 0.4% decrease and a 0.6%
increase of dose for k-Halcyon and m-Halcyon, respectively.
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Table 5.3 Evaluation of normal lung dosing for lung SBRT validation cases
including original c-Truebeam plans.
LungsPTV

kHalcyo
n

mHalcyon

cTruebea
m

k-Halcyon
vs. mHalcyon

k-Halcyon
vs. cTruebeam

m-Halcyon
vs. cTruebeam

V5Gy
(%)

12.0 ±
5.6

13 ± 5.6

12.4 ±
5.6

p < 0.001

p = n. s.

p < 0.001

V10Gy
(%)

6.9 ±
4.2

7.6 ±
4.4

7.2 ±
4.3

p < 0.001

p = 0.01

p < 0.001

V20Gy
(%)

2.7 ±
2.1

3.0 ±
2.3

2.8 ±
2.2

p < 0.001

p = 0.002

p = 0.02

MLD
(Gy)

2.5 ±
1.2

2.7 ±
1.3

2.6 ±
1.2

p < 0.001

p = 0.004

p < 0.001

5.3.3

Planning Times and Plan Complexity
The k-Halcyon planning time was less than 30 minutes. This is compared to the

estimated dedicated planning time of 180 ± 30 min (for an experienced planner) to
manually create a high-quality non-coplanar VMAT lung SBRT plan on either linac. This
estimation solely accounts for dedicated planning time and no other parts of the planning
workflow such as contouring. In practice, this is not feasible as the planners frequently
work on multiple plans simultaneously, must wait for physician’s time for contouring, or
other various checks prior to the final plan approval. Plan complexity was assessed using
total MU and its derived metrics that include MF and the corresponding BOT (Table 5.4)
as described above. There was no statistically significant difference in MU between mHalcyon and c-Truebeam plans; however, MU increased for k-Halcyon plans by 939 MU
on average (p < 0.001) compared to c-Truebeam plans. This corresponds to an increased
MF of 0.94 (p < 0.001) indicating k-Halcyon plans are modulated higher than both manual
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plans. Despite this increase of modulation, no clinically significant differences in
agreement between the Eclipse TPS and the 2nd check MU calculated dose were observed.
Due to maximum dose rate restrictions (800 MU/min), BOT inherently increases by 2.86
min and 1.66 min, on average, in k-Halcyon and m-Halcyon plans relative to c-Truebeam,
respectively.
Table 5.4 Evaluation of plan delivery metrics for lung SBRT validation cases
including original c-Truebeam plans.
Parameter

k-Halcyon

mHalcyon

cTruebeam

Total MU

4076 ±
608

3126 ±
745

3137 ±
873

p < 0.001

p < 0.001

p = n. s.

MF

4.08 ±
0.6

3.12 ±
0.7

3.14 ±
0.9

p < 0.001

p < 0.001

p = n. s.

BOT (min)

5.10 ±
0.8

3.90 ±
0.9

2.24 ±
0.6

p < 0.001

p < 0.001

p < 0.001

MC 2nd
check
results (%)

98.6 ±
1.9

99.9 ±
2.4

98.4 ±
2.0

p = n. s.

p = n. s.

p = 0.03

5.3.4

k-Halcyon k-Halcyon m-Halcyon
vs. mvs. cvs. cHalcyon Truebeam Truebeam

Left Upper Lobe Example Case
Figure 5.4 presents an example patient with a left upper lobe lesion with the typical

findings. The cumulative dose-volume histogram and corresponding 3-plane view through
the isocenter are presented for each plan. As shown in the DVH, the k-Halcyon plan
(triangle) is able to escalate the GTV minimum dose when compared to both m-Halcyon
(circles) and c-Truebeam (squares). In this case, relative to c-Truebeam, GTV minimum
dose was escalated by 4.6 Gy with minimal to no additional cost to OAR sparing. For
example, the esophagus (blue) is the most proximal OAR to the target.
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Figure 5.4 Cumulative dose-volume histogram and corresponding 3-plane view for
an example LUL patient.
Cumulative dose-volume histogram and corresponding 3-views for an example LUL
patient are presented. The cumulative DVH displays selected OAR and targets that include:
GTV (red), PTV (pink), trachea (orange), ribs(green), esophagus (blue) and lungs-PTV
(brown) for the k-Halcyon (triangles), m-Halcyon (circles) and c-Truebeam plan (squares).
In this case, the k-Halcyon plan was able to significantly increase GTV dose while
maintaining similar or better OAR sparing with similar intermediate dose spillage relative
to both m-Halcyon and c-Truebeam plan.
The k-Halcyon plan provided at least 1.3 Gy lower maximal esophageal dose
compared to the c-Truebeam plan. This dose sparing was accomplished in conjunction with
a clinically significant GTV dose escalation. Similar intermediate dose spillage can be seen
(Figure 5.4) for all three plans, with D2cm values reported to be 45% for both k-Halcyon
and m-Halcyon plans compared to 46% in the c-Truebeam plan.
5.4

Discussion
This study appears to be the first to evaluate the use of a knowledge-based planning

model for SBRT treatment of centrally located early-stage NSCLC patients using the ringmounted coplanar Halcyon Linac. While manually generated lung SBRT plans on Halcyon
were dosimetrically comparable to clinically treated plans on SBRT-dedicated Truebeam
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Linac, the lung SBRT KBP model (originally trained and validated using non-coplanar
Truebeam VMAT plans) was able to generate high-quality coplanar plans on Halcyon. This
was accomplished with a much shorter treatment planning time and eliminated interplanner variability. This KBP model offers a viable alternative to a SBRT-dedicated C-arm
linac for selected lung SBRT patients. Additionally, dose to normal lung was significantly
improved in k-Halcyon compared to both m-Halcyon and c-Truebeam plans.
A commercially available treatment planning system RayStation (RaySearch
Laboratories, Stockholm, Sweden) offers a unique feature termed “fall-back (FB)”
planning module for adaptive replanning.38 This module enables generation of 3D-CRT,
IMRT or VMAT plans based on reference plans for any treatment modality using a dosemimicking algorithm with minimal planner time and effort. Recently, a few investigators
have demonstrated that the FB planning module can convert Helical Tomotherapy plans to
C-arm linac for various sites including conventionally fractionated treatment to brain
tumors, head and neck, pelvis, prostate and lung tumors.34, 35 It was reported that these FB
plans were dosimetrically comparable to the original clinical plans and allowed for the fast
and easy transfer of patients between treatment modalities during an unforeseen period of
machine downtime.39, 40 For instance, Yuan et al. showed that FB plans would typically be
generated on average for 1 to 5 fractions of the conventionally fractionated treatment
course in the event of machine breakdown.40 Furthermore, their results suggested that an
overall < 1% dose variation can be achieved on target coverage and dose to OAR on FB
plans. These FB plans were typically generated in 10 to 20 min per case so that the patient
can be treated on another machine. As of now, this feature is not available in Varian
Eclipse. In the case of longer machine downtime, a full re-plan on another machine would
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be required, resulting in significant treatment course delay. Our KBP model could emulate
the ability of the RayStation FB planning module and enable our clinic to transfer lung
SBRT patients between Halcyon and Truebeam Linacs (if required) by generating a similar
quality plan in less than 30 minutes planning time. Furthering this thought, various
treatment units in busy and larger clinics are often not beamed matched nor commissioned
to golden beam data. Therefore, utilizing a KBP model would be vital to transferring these
patients between the modalities the same or next day –reducing the chance of delaying the
treatment course.
There are some limitations to this study and to the Halcyon Linac. An important
limitation is that, at the time of this manuscript preparation, our clinic has treated a limited
number of centrally located lung SBRT patients on Halcyon. In the future, as more lung
SBRT patients are treated on Halcyon, it would be interesting and useful to include these
patients in the training dataset to form a hybrid model with the clinical Truebeam SBRT
plans. This may further improve the k-Halcyon’s model performance and may potentially
create even higher-quality lung SBRT plans for prospective patients. Mechanically
speaking, our Truebeam Linac is equipped with a perfect pitch couch with 6-degree of
freedom (6DOF) couch corrections that allows for more accurate target localization
compared to the Halcyon Linac. Additionally, for 6MV-FFF beam, the Truebeam Linac
allows for a higher dose rate of maximum up to 1400 MU/min while the Halcyon maximum
achievable dose rate of 800MU/min (increasing the beam-on time). This dose-rate
discrepancy allows for treatments to not be clinically impractical as a 5-fraction treatment
scheme required lower MU per fraction to be delivered the prescribed dose. Meaning, this
added BOT can be offset with regard to overall treatment time using the Halcyon’s “one-
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step patient set-up” capabilities as described above. However, as of now, Halcyon may not
be suitable to treat lung SBRT patients with other commonly used extremely large fraction
sizes (e.g., 54–60 Gy in 3 fractions or 30–34 Gy in 1 fraction) 41-43 due to relatively longer
treatment time. Future work will include investigating the feasibility of utilizing KBP
models to generate lung SBRT plans with other fractionation schemes for both centrally
and peripherally located lung tumors on Halcyon Linac.
5.5

Conclusion
This study reports on the plausibility of generating lung SBRT plans for centrally

located early-stage NSCLC patients on ring-mounted Halcyon Linac using a previously
trained and validated Truebeam KBP model. It has been demonstrated that the KBP model
can be used to generate high-quality lung SBRT plans on the Halcyon Linac that are
dosimetrically equivalent or better quality when compared to manually generated Halcyon
and SBRT-dedicated Truebeam plans. This lung SBRT model is capable of quickly
generating SBRT plans to support a curative SBRT program for centers by assuring that
treatments are delivered in a safe and consistent manner potentially allowing for offline
adaptive re-planning, if needed. Additionally, the results of this study indicate that KBP
models can be cross-compatible between SBRT dedicated C-arm and O-ring linacs for lung
SBRT. It is clinically useful to enable a clinic’s ability to facilitate a smooth transfer of
patients between treatment machines as it will ensure minimal to no treatment course
disruption. This model can be shared and may provide confidence in centers equipped
solely with the Halcyon Linac in the treatment of lung SBRT in the future. It may also be
a great option for diverse centers with a high SBRT volume, or for patients who require an
immediate SBRT treatment.
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CHAPTER 6. INNOVATIONS AND CLINICAL IMPACT
6.1

Chapter 2: Clinical Evaluation of Photon Optimizer (PO) MLC Algorithm for
Stereotactic, Single-Dose of VMAT Lung SBRT
Chapter 2 explains the dosimetric evaluation of a newly configured PO-MLC

positioning optimization algorithm in the Varian Eclipse TPS that is mandatory for
generating RapidPlan models. All dosimetric comparisons were against its predecessor the
PRO for two different calculation grid-size (CGS). We hypothesized that the PO MLC
algorithm would not clinically affect final plan quality but may be subject to more
intermediate dose spillage. The study found that the PO 1.25 mm CGS yielded acceptable
plan quality compared to the PRO MLC algorithm. However, while minimally and not
clinically relevant, a slight increase of intermediate dose-spillage was observed. For
example, PO 1.25 mm CGS reported an average maximal dose 2 cm away from the target
in any direction to be 50.03 ± 6.94% whereas the PRO 2.5 mm CGS reports 47.4 ± 4.6%.
The PO algorithm is currently used for all prospective lung SBRT patient’s treatments in
the clinic.
Clinical Innovation #1: PO-MLC algorithm can be used for RapidPlan modeling in
Eclipse TPS.
Many of the previously treated lung SBRT patient’s plans were optimized using the
PRO algorithm which fundamentally functions differently than the PO-MLC algorithm.
For the PO algorithm, the structures, dose-volume histogram calculations, and dose
sampling are defined spatially using a single matrix over the image instead of a point-cloud
model defining structures that was used in the PRO algorithm. This was of the great interest

to characterize as it was necessary to understand the benefits and limitations of the new PO
algorithm for lung SBRT planning. Meaning, if the PO was underperforming compared to
previously generated plans (with PRO algorithm) that needed to be taken in account in
optimization and plan selection for prospective RapidPlan modeling to be successfully
completed. The study indicated that the PO 1.25 mm CGS plans can be used for RapidPlan
modeling.
6.2

Chapter 3: Development and Clinical Validation of a Robust KBP Model for SBRT
of Centrally Located Lung Tumors

Chapter 3 describes the development and clinical validation of a robust
knowledge-based planning model for SBRT treatments of centrally located lung tumors
using a non-coplanar VMAT technique. The new KBP model was created using 86
previously treated lung SBRT training plans and validated with 20 independent plans.
Additionally, it was further evaluated for its ability to improve clinical workflow and
offline adaptive replanning capabilities by varying the CGS of the PO optimizer. We
hypothesized that this new KBP model would create high-quality lung SBRT plans
faster, compliant with RTOG standards and would allow for slight dose escalation
(50 to 55 Gy in 5 fractions) in tumors near adjacent OAR. The results of this study
show that KBPs were similar or better to manually generated clinical plans based on
extensive target and dosimetric metrics in a shorter clinically relevant time. For instance,
KBPs provided better normal lung sparing for an average minimum GTV dose increase of
1.1 Gy (p = 0.05).
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Clinical Innovation #1: Significant reduction of ‘simulation-to-treatment’ start time from
7 to 3 working days.
The standard time it takes a patient to receive their initial CT simulation to the start
time of their first treatment is approximately 7 working days using a manual planning
process. This study reported the that average time it takes a fully dedicated, experienced
SBRT planner to manually generate a high-quality lung SBRT plans is 129 minutes.
However, in our clinic and others likewise, the majority of the planners (dosimetrists) are
required to split their time between multiple patients’ plans and therefore are typically
given at least 3 of those 7 working days to complete a lung SBRT plan. Patients who present
for retreatment of same or adjacent treatment sites, difficult geometry (tumor size and
location), or avoidance areas may require even more planning time. In addition to the
superior plan quality, the KBP model generated in this study is the first to offer the
significant reduction of the ‘simulation-to-treatment’ time down to 3 working days as it
can generate a high-quality lung SBRT plan in under 30 minutes with minimal planner
burden. Meaning, rather than meticulously adjusting constraints over multiple
optimizations, a planner can now simply run the automatic optimization process and be
confident in most cases that after one optimization the plan is ready for a physician’s
evaluation. By quickening the planning process, this still allows for at least 2 working days
for other required processes (e.g., contouring, plan review, approval and physics 2nd
checks, and quality assurance check) to be performed under a reasonable timeline. Thus,
offering optimal lung SBRT treatments to the patients in a timely manner. This will benefit
a busy clinic and improve their capacity to safely treat more lung SBRT patients in the
future.
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Clinical Innovation #2: Enabled offline adaptive re-planning capabilities for lung SBRT.
Along with the development of a novel KBP model for lung SBRT of centrally
located lesions, this study was also the first to evaluate the CGS effects in the context of
KBP and offline adaptive re-planning. It was found that by increasing the CGS to 2.5 mm
(in lieu of 1.25 mm CGS), minimal negative dosimetric impact occurred for faster plan
generation time. On average, plans could be generated in under 5 minutes enabling the
ability to perform same or next day of offline adaptive replanning, if needed. In select
cases, offline adaptive replanning is warranted to account for patient weight loss, poor daily
set-up, or tumor size shrinkage/expansion during the course of lung SBRT treatment.
Without a KBP model, the standard ‘simulation to treatment’ time still applies and may
negatively impact patient treatment.
6.3

Chapter 4: An Automated KBP Routine for SBRT of Peripheral Lung Tumors via
DCA-Based VMAT
Chapter 4 discusses the development of a KBP routine for SBRT of peripherally

located early-stage NSCLC tumors via dynamic conformal arc (DCA)-based VMAT. This
routine required the development of a KBP model and was trained with 70 previously
treated, high quality clinical plans and validated with another 20 independent clinical lung
SBRT plans. It was hypothesized that by incorporating traditional DCA-based dose
before VMAT optimization, this hybrid KBP routine would help mitigate plan
complexity and create high-quality VMAT lung SBRT plans in a clinically relevant
shorter time to manual planning. As with the centrally located KBP model, the results
of this routine created plans of similar or better quality than clinically treated plans.
Importantly, when compared to clinical plans, the KBPs that were not generated using the
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proposed routine increased total MU on average by 1316 (p < 0.001) whereas when the
routine was deployed total MU was on average decreased by 1114 MU in these plans–
significantly improving plan complexity and delivery efficiency.
Clinical Innovation #1: Development of a novel automated planning routine for peripheral
lung SBRT.
An automated planning routine was developed that couples the benefits of a
traditional DCA-based dose technique with an automated modern knowledge-based
VMAT optimization engine with minimal deviation from traditional planning workflow.
To begin, dynamic conformal arcs and collimator angles are first manually selected by the
planner. An MLC is then added to each arc and fit with a 2 mm margin around the PTV. A
new MLC aperture shaper controller (ACS) found in the most recent PO-MLC algorithm
is then adjusted from its default setting of ‘low’ to ‘very high’ strength and a 3D-DCAbased dose is calculated. If necessary, field weights are adjusted to give a practical starting
point for future KBP-VMAT optimization. Once the base dose is adjusted (if necessary),
the VMAT optimization window is launched and the DVH-estimations starts with
objectives and associated priorities as previously created by the KBP model. This proposed
method can easily be adopted by any planner and could enhance the final plan quality with
less burden than manual planning, by generating lung SBRT plans faster enabling the
potential of offline adaptive replanning.
Clinical Innovation #2: Reduction of plan complexity associated with lung SBRT KBP
model due to the DCA-based VMAT routine.
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As indicated by the previously generated model, KBP in the context of lung SBRT
planning has the tendency to increase total MU and increase overall plan complexity. This
may lead to unintended treatment delivery errors such as the interplay effect or small field
dosimetry errors. Conversely, initial planning approach via DCA-based dose significantly
reduces the total MU, improves treatment delivery confidence as it utilized larger MLC
aperture openings and keeps the target in the open beamlets throughout the treatment
duration. This proposed routine helps take advantage of the benefits of both KBP and more
traditional techniques through its ability to lower overall plan complexity and improve
treatment delivery accuracy. This will benefit the patient’s treatment by improving safety,
treatment accuracy and reduce the overall treatment time on the table.
6.4

Chapter 5: Fast Generation of Lung SBRT Plans with KBP model on O-ring
Halcyon Linac
Chapter 5 discusses the fast treatment planning feasibility of SBRT for centrally

located lung tumors on the ring-mounted Halcyon Linac via a previously validated C-arm’s
KBP model. This novel KBP model was adapted from the model described in Chapter 3
to optimally generate lung SBRT plans on Halcyon linac and was further validated with
another set of 20 independent lung SBRT patient’s plans. We hypothesized that using the
KBP model, prospective coplanar VMAT lung SBRT plans on the novel O-ring
Halcyon linac will have similar or better-quality plans to SBRT-dedicated Truebeam
plans. The results of this study confirmed that when compared to manually generated
Halcyon plans, the KBP model generated plans were similar or better quality when
compared to the clinically treated plans on the C-arm Truebeam linac. Additionally, KBPs
increased maximal target dose by 2.9 Gy (p < 0.001) while uniformly lowering normal
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lung tissue dose compared to clinical plans indicating that coplanar restrictions on the
Halcyon can be overcome while using the previously generated KBP model.
Clinical Innovation #1: KBP training data is cross-compatible between an SBRTdedicated C-arm linac and a novel O-ring Halcyon linac.
There is no current literature available that describes training datasets and clinically
validating a KBP model for lung SBRT with the Halcyon Linac. Meaning, being a new
treatment platform, there is a lack of clinical training dataset used to develop a KBP model
solely based on Halcyon treatments. Therefore, a KBP model originally built for noncoplanar VMAT treatments on a Truebeam linac was successfully adapted for use on the
Halcyon linac. This model outperformed manually generated plans for the Halcyon linac
and plan quality was similar or even better than corresponding clinical Truebeam plans.
This is of great interest to many clinics that do not have training datasets available for
multiple treatment machines but wish to deploy a KBP model across their clinic.
Clinical Innovation #2: KBP model could facilitate a smooth transfer of lung SBRT
patients between two treatment platforms – potentially overcoming unanticipated longer
machine downtime.
While in most cases the SBRT-dedicated Truebeam linac is the preferred treatment
modality of the treating physicians, the results of this study suggest that the Halcyon is a
viable alternative treatment option for selected lung SBRT patients. This is important as it
enables a clinic to account for unintended longer machine downtime or relieve a single
machine’s burden in a busy SBRT clinic. By enabling both modalities for lung SBRT
treatment options, this will lessen the chance of treatment course disruption. Moreover, in
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these high-volume SBRT clinics, fast generation (< 30 min) of a KBP model could help
distribute workload equally across machines allowing access to high-quality lung SBRT
care to more patients, especially to those requiring immediate treatments. Moreover, for
centers equipped solely with the Halcyon linac or are inexperienced planners in lung SBRT
treatments, this model can be a tremendous help to increase their confidence in treatments.
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CHAPTER 7. STUDY LIMITATIONS AND FUTURE RESEARCH DIRECTIONS
7.1

Study Limitations
There is full confidence that the KBP models created as part of this dissertation will

produce high-quality, VMAT lung SBRT plans for prospective patients in a clinically
shorter planning time than manually generated plans on both treatment platforms.
However, each study presented in this dissertation is subject to some limitations that should
be mentioned.
In Chapter 2, the PO-MLC algorithm was dosimetrically characterized and
validated against its predecessor PRO algorithm. This dosimetric evaluation was
exclusively compared for patients who received 30 Gy in 1 fraction in hopes of better
highlighting any clear dosimetric deficiencies in the algorithm configuration. The major
drawback of this method was there was limited patient datasets available for this dosing
scheme. The single fraction SBRT is not the most common fractionation scheme used in
our clinic; therefore, the study may not have enough power to meaningfully interpret the
statistics presented. However, we believe that other treatment schemes for lung SBRT will
have similar dosimetric characteristic of the PO-MLC algorithm, as demonstrated by
satisfying all the RTOG compliance criteria with the KBPs.
Both Chapters 3 and 4 developed and validated new KBP models for lung SBRT
for either centrally or peripherally located tumors. In both cases, the development and
characterization of the models were furthered whereas Chapter 3 investigated CGS effects
with KBP modeling and Chapter 4 proposes a routine to minimize plan complexity
associated with KBP while using a DCA-based VMAT approach. Due to the similarities
of these models, both studies demonstrated similar limitations and therefore will be

discussed concurrently. The most important limitation to each chapter is that some patients
presented anatomical geometries that were simply too difficult for each KBP model to
perfectly to predict an optimal lung SBRT plan. While this is rarely the case, it does limit
the full robustness of these models. There is minimal training data available for these
exceptionally difficult cases, so a combination of knowledge-based and manual planning
is recommended and feasible with the newly generated KBP models. In terms of model
development, we are confident that we chose an appropriate amount of training datasets
for each KBP model. However, due to limited available literature and resources (besides
manufacture guidelines), it cannot be said for certain this was the exact number of treatment
plans needed to ensure the highest performing model. A robust study slowly stepping the
number of training plans is warranted. Another limitation to this work is if these KBP
models are to be shared and adapted with other clinics; it will be necessary they have an
identical or a newer version of our treatment planning system. This includes dose
calculation algorithms, licensure for the commercialized knowledge-based planning
software, and training for the planners. Although, an important thing to note is that most
clinics operate on the same treatment planning system as the University of Kentucky
Medical Center, therefore we anticipate only a few major institutions would not have the
system requirements to adapt the lung SBRT models. Lastly, only the model described in
Chapter 3 has been deployed clinically for a few patients’ treatments in our center.
Therefore, the studies presented in these chapters do not include patient follow-up results
for a comparison of the treatment outcomes corresponding to the lung SBRT treatments
delivered by manually generated plans.
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Chapter 5 describes the dosimetric evaluation of a KBP model that was adapted
from the one presented in Chapter 3. Specifically, it sought to investigate if a KBP model
can be utilized to generate prospective lung SBRT treatments on the new O-ring Halcyon
Linac. While some limitations are common to the ones presented for Chapters 3 and 4,
the change of modalities presents unique limitations to the study. As a recently installed
new machine, the first limitation was the lack of training datasets available for lung SBRT
treatments on Halcyon platform. As of now, minimal clinical data exist for lung SBRT on
the Halcyon and this may ultimately affect the final model performance because the model
is not learning what is feasible on Halcyon. Additionally, the Halcyon has two important
system limitations compared to a SBRT-dedicated Truebeam linac that should be
mentioned. Mechanically, the Halcyon’s highest achievable dose rate is limited to 800
MU/min (compared to 1400 MU/min for 6MV-FFF Truebeam) and will significantly
increase beam-on-time potentially decreasing the overall treatment delivery efficiency.
This may affect more extreme hypofractionated treatment schemes rendering longer beamon-times that may not be clinically optimal for treating lung SBRT patients on Halcyon.
Additionally, target localization may be impacted relative to Truebeam treatments as the
Halcyon is not equipped with a 6 degrees-of-freedom couch (6-DOF) yet. Rather, the
Halcyon can only account for 3-degrees of translational corrections. While not always
available on C-arm linacs, many physicians prefer the use of the 6-DOF couch corrections
as it improves the target localization accuracy for lung SBRT.
7.2

Future Research Directions
This dissertation laid the fundamental groundwork for expanding a lung SBRT

program in many different clinically relevant and important directions. The first and
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foremost expansion of this dissertation is as these KBP models are deployed clinically,
patient follow-up data should be recorded to evaluate the positive clinical impact of these
KBP models. While it is not expected to observe a significant change, it is important to
ensure that KBPs at least maintain or improves the local control observed in manual
planning a lung SBRT treatment. However, any marginal increase of tumor local control
or decrease in normal lung tissue toxicity (i.e., radiation induced pneumonitis) will have
significant impact on patients’ outcomes if they require radiation treatment in the future.
The next direction is to continue expanding KBP lung SBRT modeling for more
robust uses in busy SBRT centers. This work solely encompasses single lesion modeling,
but there is growing interest in the treatment of synchronous oligometastatic multi-lesion
lung SBRT. Recently, many patients have received multi-lesion lung SBRT treatments at
the University of Kentucky Medical Center.1,2 Therefore, utilizing the validated models as
a baseline, it is possible to inject select multi-lesion lung SBRT plans into the training
datasets in aim to generate a submodel. This should enhance the predicting power of a KBP
model in a synchronous multi-lesion setting. This will ultimately increase the use of lung
SBRT KBP in the clinic, for the fast, safe and effective treatment of synchronous lung
lesions. The adapted model described in Chapter 5 solely used a C-arm Truebeam Linac
training dataset for prospective treatment planning on the Halcyon Linac. In future, as
physicians treats more lung SBRT patients on Halcyon, clinical lung SBRT training
datasets will slowly be accumulated and can be used for further KBP development. An
interesting and relevant study related to this dissertation would be to use these newfound
datasets for the creation and development of a sole Halcyon trained model. While
potentially tedious, it would also be of great interest to slowly replace the C-arm training
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datasets in the currently developed model with new clinical plans treated on the Halcyon.
This should effectively characterize the cross-compatibility of the training data between
Halcyon and Truebeam linacs. Meaning, as training plans were replaced, an observation
can be made of the dosimetric impacts between prospectively generated Halcyon and
Truebeam lung SBRT plans.
Along with different modality and multi-lesion data becoming available, there is
also more data available for patients treated at 30 Gy in 1 fraction than at the start of this
dissertation. If the single treatment planning datasets were utilized for a sub-model
generation from the KBP model described in Chapter 4, perhaps it could then be used to
cover multiple prescriptions (depending on tumor size and geographical location).
Moreover, the proposed DCA-based VMAT planning routine can be deployed to see the
dosimetric advantages between manually generated clinical plans and the new DCA-KBP
plans for single-dose of lung SBRT treatments. The most interesting expansion of this
dissertation will be the adaptation and further development of a model designed to treat
large lung tumors (>5 cm in diameter) with a simultaneous integrated boost (SIB) technique
–potentially escalating higher dose to the hypoxic tumor core. Traditionally, lung SBRT is
limited to tumors less than 5 cm, as anything larger presents difficulty in dose escalation
because of normal tissue toxicity considerations. However, if the dose can be escalated via
a KBP-SIB approach (i.e., 60 Gy to GTV and 50 Gy to PTV in 5 fractions) while respecting
dose tolerances to the adjacent OAR, these concerns can be partially mitigated and curative
SBRT treatments can be offered to this patient cohort. At the University of Kentucky
Medical Center, a few patients have been manually planned and treated using this proposed
approach, with clinical follow-up results actively being accrued. It is very difficult to
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manually generate these lung SBRT plans, however, it may be significantly easier to plan
with a combination of manual and KBP approaches. A full hybrid approach should be
developed to assist in managing these difficult and complex patients.
In addition to expanding lung KBP modeling capabilities, the proposed routine in
Chapter 4 can be expanded in the future to support full automation of the entire treatment
planning process. As of now, the routine only partially automates the lung SBRT planning
process during the inverse optimization phase. To improve the overall planning time, the
first step can be to incorporate an atlas-based auto-contouring feature of select OAR. Many
structures (e.g., heart, spinal cord, total lung) do not heavily deviate between patients, yet
require slice by slice delineation by the planner or the treating physician. This would
significantly further shorten ‘simulation-to-treatment’ time and may only require physician
intervention to contour the target structures. After contouring is done, a fully automated
script can be written that will automatically deploy the isocenter location to the target
center and auto-deploy beams/arc geometry from a template on a per-patient basis. In many
cases, arc geometry and collimator angles are similar and therefore can become an
automated process with the option of manual tweaking. Additionally, the DVH-estimation
can be generated automatically with scripting and a fixed number of optimizations can be
set for generating optimal lung SBRT plans. This will significantly reduce a planner’s
burden, standardize the treatment geometry, and allow for increased confidence in
treatments as the total number of optimizations is controlled. Paired with fully automating
a treatment planning routine or a sole KBP model, a full plan evaluation and integration of
an offline adaptive replanning process merits future investigation. Offline adaptative
replanning is a condensed conventional planning workflow designed to address the gradual
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changes of patient’s treatment throughout the treatment course. There are many
uncertainties and questions that need to be answered before fully implementing offline
adaptive replanning in the clinic. This includes developing recommendations as to how
often and when to make the decision to adapt and re-plan the treatment course. For instance,
it should be decided what criteria of changes should trigger a re-plan (e.g., tumor size
change, patient weight change, automatically after a certain number of fractions or
difficulty in reproducing patient set up). Additionally, a complete study characterizing the
clinical benefits of replanning the patient’s treatment is required. When this information is
gathered and analyzed, the proposed routine should be deployed on a limited basis with
patient follow-up data ascertained.
In line with exploring the benefits of KBP for lung SBRT treatments via offline
adaptive replanning, beyond this dissertation a study should be completed to explore the
quality assurance (QA) benefits of a KBP model. For example, a lung SBRT KBP can be
used for prospective patient-specific QA checks. Since a KBP model is derived from
historical high-quality planning datasets, all prospective manually planned treatments
should fall into some margin of agreement with a KBP DVH estimate. It would be
necessary to define these cut-off values (e.g., total MU tolerance, OAR dose limits, plan
complexity) to help maintain generating consistent plan quality and to further reduce interplanner variability for manual planning (if needed). Lastly, developing and validating these
KBP models for lung SBRT treatments as part of this dissertation serves as the basis for
the transition of modern-day automated treatment planning. In the near future, multicriteria optimization (MCO) will be utilized by planners to generate hundreds of plans at a
time based on a clinical model library.4 In this dissertation, the KBP models produced are
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only capable of generating only one plan at a time for a physician’s review. However, when
MCO becomes widely available clinically, multiple plans will now be able to be adapted
in real-time to better suit the patient and physician’s needs. For example, a slider bar
window would be available to adjust the dose to an OAR or for the better target coverage
on-the-fly rather than requiring another full optimization series which may delay the
patient’s treatment. In summary, developing and further validating KBP models for lung
SBRT treatments as part of this dissertation successfully laid the groundwork for important
and interesting future research endeavors. These potential routes will better serve complex
patients, optimize clinic workflow, and provide important information to the greater
medical physics community for the highest quality of patient care.
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CHAPTER 8. CLOSING ARGUMENTS
The research presented in this dissertation describes the generation of novel KBP
models for SBRT treatments of both centrally and peripherally located tumor locations
using a non-coplanar VMAT geometry. These models also support treatments with a
traditional C-arm linac and a newly installed O-ring Halcyon Linac; ultimately expanding
a robust lung SBRT program at the University of Kentucky Medical Center. One of the
parallel goals with model development was to eliminate the issues associated with
manually planning and condense the current lung SBRT clinical workflow to support a
timelier treatment manner. These models, in many cases, enhance tumor core dose with no
additional cost to adjacent critical structures sparing. Meaning, they are able to generate
plans with excellent quality relative to clinically treated plans. The models described in
this dissertation eliminate inter-planner variability by standardizing a clinic’s thoracic lung
SBRT program, thus increasing patient safety. Moreover, by generating these high-quality
plans, a clinic’s workload capacity can be increased to provide the highest quality of care
to more patients in the future. This is accomplished by using the KBP models generated in
this dissertation to shorten the overall ‘simulation-to-treatment’ time to as few as 3 working
days from traditional 7 days. In select cases, these KBP models may help condense this
time down even quicker to support offline adaptive replanning that allows a clinician to
account for physiological changes in a patient during the course of treatment. Overall, this
dissertation enables standardization of a lung SBRT program and provides a basic
modeling framework for other clinics (as well as other disease sites) to emulate or simply
adapt these sharable lung SBRT models. With fast generation of KBPs (< 30 min), the
model has the potential to transfer lung SBRT patients to the O-ring Halcyon to account

for unforeseen longer machine downtime and complete the patient’s treatment course in a
timely manner. The tools and techniques developed in this dissertation my potentially help
inexperienced or busy centers provide more high-quality patient care to select prospective
early-stage NSCLC patients who require SBRT treatments in a timely manner.
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APPENDICES
APPENDIX 1. GLOSSARY
Glossary of Common Terms. A list of common acronyms used throughout this
dissertation with corresponding definitions is presented.
3DCRT
6DOF
AAA
BOT
c-Truebeam
CGS
CI
CT
DCA
DLO
DVH
ESAPI
FFF
GD
GED
GI
GTV
GY
HI
iCBCT
IMRT
IRB
ITV
k-DCA
k-Halcyon
KBP
LINAC
LLL
LUL
m-Halcyon
MF
MIP

3-Dimensional Conformal Radiation Therapy
6 Degrees of Freedom
Analytical Anisotropic Algorithm
Beam-on-Time
Clinical Truebeam VMAT Lung SBRT Plan
Calculation Grid Size
Conformity Index
Computed Tomography
Dynamic Conformal Arcs
Dose Limiting Organs
Dose Volume Histogram
Eclipse Scripting Application Programming Interface
Flattening Filter Free
Gradient Distance
Geometry Expected Dose
Gradient Index
Gross Tumor Volume
Gray
Heterogeneity Index
Iterative Cone-Beam Computed Tomography
Intensity Modulated Radiation Therapy
Institutional Review Board
Internal Target Volume
DCA-Based VMAT Lung SBRT Plan
Knowledge-Based Optimized Halcyon Lung SBRT Plan
Knowledge-Based Planning/Plan
Linear Accelerator
Left Lower Lobe
Left Upper Lobe
Manually Optimized Halcyon Lung SBRT Plan
Modulation Factor
Maximum Intensity Projection

MLC
MLD
MU
n-VMAT
NSCLC
OAR
PCA
PCS
PO
PO-VMAT
PRO
PRO-VMAT
PTV
QA
RLL
RTOG
RUL
SBRT
SRS
STD
TPS
VMAT

Multi-Leaf Collimator
Mean Lung Dose
Monitor Units
Clinical Truebeam VMAT Lung SBRT Plan
Non-Small-Cell-Lung-Cancer
Organs at Risk
Principal Component Analysis
Principal Component Score
Photon Optimizer
Photon Optimizer Lung SBRT Plan
Progressive Resolution Optimizer
Progressive Resolution Optimizer Lung SBRT Plan
Planning Target Volume
Quality Assurance
Right Lower Lobe
Radiation Therapy Oncology Group
Right Upper Lobe
Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery
Standard Deviation
Treatment Planning system
Volumetric Modulated Arc Therapy
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APPENDIX 2. KNOWLEDGE-BASED PLANNING INTERFACE
General RapidPlan Interface View: The standard RapidPlan interface is presented. This
window enables the user to add model information, publish, train and review the fitting
statistics while generating the model.

Model and Structures Window: The user may assign manual and automatic target and
normal tissue objectives in this section of the interface. The KBP algorithm does not
recommend any objectives and it is incumbent to the users to select the appropriate
objectives to ensure optimal model performance is achieved.

Plan Selection and Matching Window: This diagram provides a summary to the user of
which plans were added to the model via External Beam Planning. Additionally, the user
may choose which structures contoured on the original clinical plan will be included in the
model initially and after outlier verification.

Summary of Training Results Tab: The model reports the overall fitting statistics for
each trained structure set. This includes the number of structures that reported an in-field
volume along with the corresponding potential plan outlier number.
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Summary of Outlier Statistics Tab: The DVH algorithm flags what it interprets to be the
largest outlier plans with the corresponding statistics (most critical in red). The user should
manually review these recommendations and conclude whether or not it is a true outlier.
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APPENDIX 3. EXAMPLE PLOTS AND STATISTICS
Geometric Plot for Normal Lung Structure: The geometric plot displays the distribution
of all relevant statistics and volumes for the user to review. The primary purpose of this
part of the process is to identify the geometric outliers. In statistically perfect model, all
data points ideally would fall within the 10 and 90 percentile distribution. However, in
practice this is not clinically feasible.

Regression Plot for Normal Lung Structure: The regression plot for a selected structure
is shown below that provides correlation between the first DVH PCS and geometric PCS.
In practice, all data points should fall within a reasonable margin of the standard deviation
line and should mostly remain relatively grouped along the X-axis. This is a powerful tool
to identify geometric outliers as well.

Residual Plot for Normal Lung Structure: The residual plot shown below is an important
tool for not only identifying dosimetric outliers, but to also evaluate how well the DVH
estimate is representing the actual training datasets. Meaning, similar to the geometric plot,
a perfect model all data points would fall exactly (or within a STD) of the regression line.

Dose Volume Histograms for Normal Lung Structure: All DVHs for all plans that are
included in the model are presented to the user (Chapter 4 model). As stated by the vendor,
the primary purpose of this window is to ensure there are no incorrect structure matches
and all DVHs mostly are similar.
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In-Field Region Dose Volume Histograms for Normal Lung Structure: The DVHs for
in-field regions of all plans corresponding to that structure are presented to the user
(Chapter 4 model). When selected, a plan will display its predicted DVH band and the
actual plot should fall somewhere within that band. This provides confidence to the user
the model is performing optimally.

Summary of Outlier Statistics for Normal Lung Structure: The DVH estimation will
provide important fitting statistics to help the user gauge and remove potential dosimetric
and geometric outliers. Per vendor information, the following statistics and corresponding
definitions are presented. Cook’s distance (CD) represents which plans are most
influencing a model’s performance (shown in red). Modified Z-score (mZ) measured the
difference of an individual structure from the training sample’s median value. The student
residual (SR) correlates effectively the absolute difference between the original data and
the estimated data using only the in-field DVH estimates. Lastly, the areal difference of
estimate (dA) measures the difference between the original and reconstructed data,
meaning, how much area remains between predicted and actual DVH normalized by a
STD. Essentially, it is similar to the SR, but it considers the entire structure DVH.
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APPENDIX 4 EXAMPLE PATIENT WITH DVH AND ESTIMATION
Example KBP Optimization DVH and Axial View: Target (red = GTV, pink = PTV)
and select OAR (green = ribs, purple = D2cm+5mm, light green = lungs-PTV, yellow =
cord, blue = heart) with their actual DVH and predicted STD (including automatically
generated optimization objectives) are shown. For most patients, the OAR DVH should
fall somewhere within the predicted DVH estimation band (see bottom left of the DVHs).
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